| 1 |
Tariq M, de Souza AH, Bensellam M, Chae H, Jaffredo M, Close AF, Deglasse JP, Santos LRB, Buemi A, Mourad NI, Wojtusciszyn A, Raoux M, Gilon P, Broca C, Jonas JC. Prolonged culture of human pancreatic islets under glucotoxic conditions changes their acute beta cell calcium and insulin secretion glucose response curves from sigmoid to bell-shaped. Diabetologia 2023;66:709-23. [PMID: 36459178 DOI: 10.1007/s00125-022-05842-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Rasalam R, Abdo S, Deed G, O'Brien R, Overland J. Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence. Diabetes Obes Metab 2023;25:901-15. [PMID: 36541153 DOI: 10.1111/dom.14953] [Reference Citation Analysis]
|
| 3 |
Díaz A, Vázquez-Roque R, Carreto-Meneses K, Moroni-González D, Moreno-Rodríguez JA, Treviño S. Polyoxidovanadates as a pharmacological option against brain aging. J Chem Neuroanat 2023;129:102256. [PMID: 36921908 DOI: 10.1016/j.jchemneu.2023.102256] [Reference Citation Analysis]
|
| 4 |
Sewaybricker LE, Huang A, Chandrasekaran S, Melhorn SJ, Schur EA. The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. Endocr Rev 2023;44:281-96. [PMID: 36251886 DOI: 10.1210/endrev/bnac023] [Reference Citation Analysis]
|
| 5 |
Liu SC, Chuang SM, Wang CH, Chien MN, Lee CC, Chen WC, Leung CH, Lin JL. Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus. Diabetes Obes Metab 2023;25:700-6. [PMID: 36321411 DOI: 10.1111/dom.14912] [Reference Citation Analysis]
|
| 6 |
Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, Wullenweber P, Haupt A, Kazda C. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol 2023;11:158-68. [PMID: 36758572 DOI: 10.1016/S2213-8587(22)00388-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Hao S, Umpierrez GE, Vellanki P. Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2. Endocrinol Metab Clin North Am 2023;52:39-47. [PMID: 36754496 DOI: 10.1016/j.ecl.2022.07.004] [Reference Citation Analysis]
|
| 8 |
Sousa AS, Passos MP, Ruberti OM, Jarrete AP, Delbin MA. Evaluation of coronary function in female rats with severe type 1 diabetes: Effects of combined treatment with insulin and pyridoxamine. Microvasc Res 2023;146:104474. [PMID: 36592817 DOI: 10.1016/j.mvr.2022.104474] [Reference Citation Analysis]
|
| 9 |
Yao J, Zhang M, Zhang X, Zhang J. Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis. Diabetes Ther 2023. [PMID: 36809495 DOI: 10.1007/s13300-023-01369-6] [Reference Citation Analysis]
|
| 10 |
Chiarito M, Sanz-Sanchez J, Piccolo R, Condello F, Liccardo G, Maurina M, Avvedimento M, Regazzoli D, Pagnotta P, Garcia-Garcia HM, Mehran R, Federici M, Condorelli G, Diez Gil JL, Reimers B, Ferrante G, Stefanini G. Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. Cardiovasc Diabetol 2023;22:28. [PMID: 36747244 DOI: 10.1186/s12933-023-01744-4] [Reference Citation Analysis]
|
| 11 |
Dalco LJ, Dave KR. Diabetic Rodent Models for Chronic Stroke Studies. Methods Mol Biol 2023;2616:429-39. [PMID: 36715951 DOI: 10.1007/978-1-0716-2926-0_30] [Reference Citation Analysis]
|
| 12 |
Pardhan S, Upadhyaya T, Smith L, Sharma T, Tuladhar S, Adhikari B, Kidd J, Sapkota R. Individual patient-centered target-driven intervention to improve clinical outcomes of diabetes, health literacy, and self-care practices in Nepal: A randomized controlled trial. Front Endocrinol (Lausanne) 2023;14:1076253. [PMID: 36742401 DOI: 10.3389/fendo.2023.1076253] [Reference Citation Analysis]
|
| 13 |
Huang X, Huang J, Li X, Chen L. Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clin Pharmacol Drug Dev 2023. [PMID: 36642944 DOI: 10.1002/cpdd.1219] [Reference Citation Analysis]
|
| 14 |
Wan W, Qin Q, Xie L, Zhang H, Wu F, Stevens RC, Liu Y. GLP-1R Signaling and Functional Molecules in Incretin Therapy. Molecules 2023;28. [PMID: 36677809 DOI: 10.3390/molecules28020751] [Reference Citation Analysis]
|
| 15 |
Da Moura Semedo C, Bath PA, Zhang Z. Social Support in a Diabetes Online Community: Mixed Methods Content Analysis. JMIR Diabetes 2023;8:e41320. [PMID: 36607714 DOI: 10.2196/41320] [Reference Citation Analysis]
|
| 16 |
Chehal PK, Uppal TS, Turbow S, Fernandes G, Haw JS, Shah MK, Rajpathak S, Narayan KMV, Ali MK. Continuity of Medication Use by US Adults With Diabetes, 2005-2019. JAMA Netw Open 2023;6:e2253562. [PMID: 36716032 DOI: 10.1001/jamanetworkopen.2022.53562] [Reference Citation Analysis]
|
| 17 |
Tabatabaei Dakhili SA, Greenwell AA, Yang K, Abou Farraj R, Saed CT, Gopal K, Chan JSF, Chahade JJ, Eaton F, Lee C, Velázquez-Martínez CA, Crawford PA, Glover JNM, Al Batran R, Ussher JR. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126-34. [PMID: 36256885 DOI: 10.2337/db22-0221] [Reference Citation Analysis]
|
| 18 |
Khamis AM. Pathophysiology, Diagnostic Criteria, and Approaches to Type 2 Diabetes Remission. Cureus 2023;15:e33908. [PMID: 36819346 DOI: 10.7759/cureus.33908] [Reference Citation Analysis]
|
| 19 |
Inoue T, Yoshida K, Sasaki E, Aizawa K, Kamioka H. Effect of Lycopene Intake on the Fasting Blood Glucose Level: A Systematic Review with Meta-Analysis. Nutrients 2022;15. [PMID: 36615780 DOI: 10.3390/nu15010122] [Reference Citation Analysis]
|
| 20 |
Zhao Y, Zhang X, Liang H, Wang L. Antidiabetic agents: Do they hit the right targets? Frigid Zone Medicine 2022;2:225-243. [DOI: 10.2478/fzm-2022-0030] [Reference Citation Analysis]
|
| 21 |
Nazu NA, Wikström K, Lamidi M, Lindström J, Tirkkonen H, Rautiainen P, Laatikainen T. Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities – a register-based retrospective cohort study in Finland. BMC Prim Care 2022;23:278. [DOI: 10.1186/s12875-022-01889-3] [Reference Citation Analysis]
|
| 22 |
Mansour AA, Rahmah A, Khudhair M. Management of Type 2 Diabetes With Insulin Glargine-100 in Iraq in a Real-Life Observation. Cureus 2022. [DOI: 10.7759/cureus.31164] [Reference Citation Analysis]
|
| 23 |
Fang H, Ding Y, Xia S, Chen Q, Niu B. Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175377] [Reference Citation Analysis]
|
| 24 |
Saarinen I, Grönroos S, Hurme S, Peterli R, Helmiö M, Bueter M, Strandberg M, Wölnerhanssen BK, Salminen P. Validation of the Individual Metabolic Surgery Score for Bariatric Procedure Selection in the Merged Data of Two Randomized Clinical Trials (SLEEVEPASS and SM-BOSS). Surgery for Obesity and Related Diseases 2022. [DOI: 10.1016/j.soard.2022.10.036] [Reference Citation Analysis]
|
| 25 |
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ 2022;379:e070717. [PMID: 36191949 DOI: 10.1136/bmj-2022-070717] [Reference Citation Analysis]
|
| 26 |
Gu C, He G, Lin C. EVALUATION OF HIGH LEVELS OF SPORTS ACTIVITY AND THE BENEFICIAL EFFECT ON POSTPRANDIAL BLOOD GLUCOSE PROFILES. Rev Bras Med Esporte 2022;28:465-8. [DOI: 10.1590/1517-8692202228052022_127] [Reference Citation Analysis]
|
| 27 |
Szépkúti S, Bandur S, Kovács G, Ferenci T, Svébis MM, Turbucz P, Tabák ÁG. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocr Disord 2022;22:229. [PMID: 36104712 DOI: 10.1186/s12902-022-01139-8] [Reference Citation Analysis]
|
| 28 |
Mu X, Xiang Z, Xu Y, He J, Lu J, Chen Y, Wang X, Tu CR, Zhang Y, Zhang W, Yin Z, Leung W, Lau Y, Liu Y, Tu W. Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes. Cell Mol Immunol 2022;19:944-956. [DOI: 10.1038/s41423-022-00894-x] [Reference Citation Analysis]
|
| 29 |
Paul A, Nath Das P, Chatterjee S. A minimal model of glucose-stimulated insulin secretion process explores factors responsible for the development of type 2 diabetes. Applied Mathematical Modelling 2022;108:408-26. [DOI: 10.1016/j.apm.2022.03.035] [Reference Citation Analysis]
|
| 30 |
Da Moura Semedo C, Bath P, Zhang Z. Social Support in a Diabetes Online Community: A Mixed Methods Content Analysis (Preprint).. [DOI: 10.2196/preprints.41320] [Reference Citation Analysis]
|
| 31 |
Zeitler P, El Ghormli L, Arslanian S, Caprio S, Isganaitis E, Kelsey MK, Weinstock RS, White NH, Drews K. Deterioration of Glycemic Control in Youth-Onset Type 2 Diabetes: What Are the Early and Late Predictors? J Clin Endocrinol Metab 2022;107:e3384-94. [PMID: 35486388 DOI: 10.1210/clinem/dgac254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 32 |
Zou P, Guo M, Hu J. Evogliptin for the treatment of type 2 diabetes: an update of the literature. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2100348] [Reference Citation Analysis]
|
| 33 |
Cui X, Feng J, Wei T, Gu L, Wang D, Lang S, Yang K, Yang J, Yan H, Wei R, Hong T. Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice. iScience 2022;25:104567. [DOI: 10.1016/j.isci.2022.104567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Schnaars Y, Gaikwad S, Gottwald-Hostalek U, Klingberg U, Vadla HKC, Prathap VR. Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers. Diabetes Ther 2022;13:1215-29. [PMID: 35543870 DOI: 10.1007/s13300-022-01269-1] [Reference Citation Analysis]
|
| 35 |
Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, Mccoy RG. Emulating the GRADE Trial Using Real-World Data.. [DOI: 10.1101/2022.05.23.22275392] [Reference Citation Analysis]
|
| 36 |
Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, Macdonald R, Hollenberg MD, Hill MA. Metformin: Is it a drug for all reasons and diseases? Metabolism 2022. [DOI: 10.1016/j.metabol.2022.155223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Tews D, Gouveri E, Simon J, Marck C. A Smartphone-Based Application to Assist Insulin Titration in Patients Undergoing Basal Insulin-Supported Oral Antidiabetic Treatment. J Diabetes Sci Technol. [DOI: 10.1177/19322968221090521] [Reference Citation Analysis]
|
| 38 |
Ali MM, Hafez A, Abdelgalil MS, Hasan MT, El-Ghannam MM, Ghogar OM, Elrashedy AA, Abd-ElGawad M. Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Endocr Disord 2022;22:113. [PMID: 35488292 DOI: 10.1186/s12902-022-01031-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 39 |
Pan Q, Zhang L, Gu A, Yu D, Wang X, Zhou Y, Guo L. The Absorption of Needle-Free Insulin Aspart Through Jet Injector in Different Body Parts of Healthy Individuals. Front Endocrinol 2022;13:832726. [DOI: 10.3389/fendo.2022.832726] [Reference Citation Analysis]
|
| 40 |
Tekle Y, Hiware S, Shameem A, Atlaw D. Impact of khat leaves on glycosylated haemoglobin and lipid profile in healthy individuals in Dire Dawa, Ethiopia. SAGE Open Medicine 2022;10:205031212210944. [DOI: 10.1177/20503121221094451] [Reference Citation Analysis]
|
| 41 |
Ibrahim AM, Lawrence S, Tobón GJ. Improving Diabetes Care: A Fijian Diabetes Service Improvement Study. International Journal of Chronic Diseases 2022;2022:1-9. [DOI: 10.1155/2022/9486679] [Reference Citation Analysis]
|
| 42 |
Singla R, Gupta G, Dutta D, Raizada N, Aggarwal S. Diabetes reversal: Update on current knowledge and proposal of prediction score parameters for diabetes remission. Diabetes Metab Syndr 2022;16:102452. [PMID: 35306265 DOI: 10.1016/j.dsx.2022.102452] [Reference Citation Analysis]
|
| 43 |
Hassanein M, Al Dahi W, Radhi HT, Aimahfouz A, Al Kaabi J, Alshammari A, Alfutaisi A, Almalki MH, Malik R. Expert-Group Practical Advice on Insulin Initiation and Titration for Patients with Type 2 Diabetes in the Gulf Region. Dubai Diabetes Endocrinol J. [DOI: 10.1159/000521437] [Reference Citation Analysis]
|
| 44 |
Valeeva FV, Medvedeva MS, Khasanova KB, Valeeva EV, Kiseleva TA, Egorova ES, Pickering C, Ahmetov II. Association of gene polymorphisms with body weight changes in prediabetic patients. Mol Biol Rep 2022. [PMID: 35292917 DOI: 10.1007/s11033-022-07254-y] [Reference Citation Analysis]
|
| 45 |
Tyagi P, Koskinen M, Mikkola J, Sarkhel S, Leino L, Seth A, Madalli S, Will S, Howard VG, Brant H, Corkill D. Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide. Pharmaceutics 2022;14:553. [DOI: 10.3390/pharmaceutics14030553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Trujillo-del Río C, Tortajada-pérez J, Gómez-escribano A, Casterá F, Peiró C, Millán J, Herrero M, Vázquez-manrique R. Metformin to treat Huntington disease: a pleiotropic drug against a multi-system disorder. Mechanisms of Ageing and Development 2022. [DOI: 10.1016/j.mad.2022.111670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Kim J, Kwon HS. Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus. Diabetes Metab J 2022;46:165-80. [PMID: 35385632 DOI: 10.4093/dmj.2021.0377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Cabrera N, Cuesta SA, Mora JR, Calle L, Márquez EA, Kaunas R, Paz JL. In Silico Searching for Alternative Lead Compounds to Treat Type 2 Diabetes through a QSAR and Molecular Dynamics Study. Pharmaceutics 2022;14:232. [DOI: 10.3390/pharmaceutics14020232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 49 |
İnce İ, Altinay L. The effect of diabetes on mid-term survival of open heart surgery patients aged over 70 years. Journal of Health Sciences and Medicine 2022;5:184-8. [DOI: 10.32322/jhsm.1022665] [Reference Citation Analysis]
|
| 50 |
Liu S, Liu J, Yu Y, Si L, Tang C, Liu Z, Chen Y. What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China. Front Pharmacol 2021;12:802897. [PMID: 35002736 DOI: 10.3389/fphar.2021.802897] [Reference Citation Analysis]
|
| 51 |
Abramson A, Frederiksen MR, Vegge A, Jensen B, Poulsen M, Mouridsen B, Jespersen MO, Kirk RK, Windum J, Hubálek F, Water JJ, Fels J, Gunnarsson SB, Bohr A, Straarup EM, Ley MWH, Lu X, Wainer J, Collins J, Tamang S, Ishida K, Hayward A, Herskind P, Buckley ST, Roxhed N, Langer R, Rahbek U, Traverso G. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol 2022;40:103-9. [PMID: 34462588 DOI: 10.1038/s41587-021-01024-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 52 |
Li APZ, Kariyawasam D. Type 2 Diabetes Mellitus. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00098-0] [Reference Citation Analysis]
|
| 53 |
Pot GK, de Jong HBT, Battjes-Fries MCE, Patijn ON, Pijl H, Voshol PJ. Observational study on dietary changes of participants following a multicomponent lifestyle program (Reverse Diabetes2 Now). J Hum Nutr Diet 2021. [PMID: 34967062 DOI: 10.1111/jhn.12976] [Reference Citation Analysis]
|
| 54 |
Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 2021;396:2019-82. [PMID: 33189186 DOI: 10.1016/S0140-6736(20)32374-6] [Cited by in Crossref: 186] [Cited by in F6Publishing: 177] [Article Influence: 93.0] [Reference Citation Analysis]
|
| 55 |
Son J, Ding H, Farb TB, Efanov AM, Sun J, Gore JL, Syed SK, Lei Z, Wang Q, Accili D, Califano A. BACH2 inhibition reverses β cell failure in type 2 diabetes models. J Clin Invest 2021;131:e153876. [PMID: 34907913 DOI: 10.1172/JCI153876] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 56 |
Han S, Zhou W, Zhuang C, Chen F. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues. Bioorg Chem 2021;119:105537. [PMID: 34902644 DOI: 10.1016/j.bioorg.2021.105537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Sbraccia P, D'Adamo M, Guglielmi V. Is type 2 diabetes an adiposity-based metabolic disease? From the origin of insulin resistance to the concept of dysfunctional adipose tissue. Eat Weight Disord 2021;26:2429-41. [PMID: 33555509 DOI: 10.1007/s40519-021-01109-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 58 |
Rebello CJ, Coulter AA, Reaume AG, Cong W, Cusimano LA, Greenway FL. MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. Pharmaceuticals (Basel) 2021;14:1196. [PMID: 34832978 DOI: 10.3390/ph14111196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 59 |
Bosetti R, Tabatabai L, Naufal G, Menser T, Kash B. Comprehensive cost-effectiveness of diabetes management for the underserved in the United States: A systematic review. PLoS One 2021;16:e0260139. [PMID: 34793562 DOI: 10.1371/journal.pone.0260139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 60 |
Young TK, Li JW, Kang A, Heerspink HJL, Hockham C, Arnott C, Neuen BL, Zoungas S, Mahaffey KW, Perkovic V, de Zeeuw D, Fulcher G, Neal B, Jardine M. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program. Diabetologia 2021;64:2402-14. [PMID: 34448033 DOI: 10.1007/s00125-021-05524-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Mustafa F, Mohammed AH. Study of QT interval prolongation in asymptomatic type-2 diabetes mellitus patients with and without microalbuninuria. IJCAP 2021;8:235-240. [DOI: 10.18231/j.ijcap.2021.052] [Reference Citation Analysis]
|
| 62 |
Kumar V, Ramu R, Shirahatti PS, Kumari VBC, Sushma P, Mandal SP, Patil SM. α‐Glucosidase, α‐Amylase Inhibition, Kinetics and Docking Studies of Novel (2‐Chloro‐6‐(trifluoromethyl)benzyloxy)arylidene) Based Rhodanine and Rhodanine Acetic Acid Derivatives. ChemistrySelect 2021;6:9637-44. [DOI: 10.1002/slct.202101954] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 63 |
Kalamajski S, Huang M, Dalla-Riva J, Keller M, Dawed AY, Hansson O, Pearson ER, Mulder H, Franks PW; MetGen Plus Consortium. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. Hum Mol Genet 2021:ddab266. [PMID: 34505146 DOI: 10.1093/hmg/ddab266] [Reference Citation Analysis]
|
| 64 |
Tsimikas S, Bhatia HS. Glucose Control in Patients Undergoing PCI: What Is the Optimal HbA1c for Long-Term Outcomes? JACC Cardiovasc Interv 2021;14:398-400. [PMID: 33602436 DOI: 10.1016/j.jcin.2020.11.038] [Reference Citation Analysis]
|
| 65 |
Chen YS, Weng SJ, Chang SH, Li RY, Shane GT, Hsu JP, Yeh SW, Chang AC, Lee MJ. Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. PLoS One 2021;16:e0255405. [PMID: 34358247 DOI: 10.1371/journal.pone.0255405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Obafemi TO, Jaiyesimi KF, Olomola AA, Olasehinde OR, Olaoye OA, Adewumi FD, Afolabi BA, Adewale OB, Akintayo CO, Ojo OA. Combined effect of metformin and gallic acid on inflammation, antioxidant status, endoplasmic reticulum (ER) stress and glucose metabolism in fructose-fed streptozotocin-induced diabetic rats. Toxicol Rep 2021;8:1419-27. [PMID: 34345595 DOI: 10.1016/j.toxrep.2021.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Kawai K, Eiki J, Kanatsuka A, Motohashi S, Wakana A, Hayashi A, Iglay K, Yamazaki K, Tokita S, Maegawa H; Japan Diabetes Clinical Data Management Study Group (JDDM). Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60). Diabetol Int 2022;13:132-41. [DOI: 10.1007/s13340-021-00514-5] [Reference Citation Analysis]
|
| 68 |
Paczkowska A, Hoffmann K, Michalak M, Bryl W, Kopciuch D, Zaprutko T, Ratajczak P, Nowakowska E, Kus K. A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up. Diabetes Metab Syndr Obes 2021;14:3243-52. [PMID: 34285531 DOI: 10.2147/DMSO.S317659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 69 |
Vlacho B, Mata-Cases M, Mundet-Tudurí X, Vallès-Callol JA, Real J, Farre M, Cos X, Khunti K, Mauricio D, Franch-Nadal J. Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. Front Endocrinol (Lausanne) 2021;12:708372. [PMID: 34335477 DOI: 10.3389/fendo.2021.708372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 70 |
Fralick M, Schneeweiss S, Redelmeier DA, Razak F, Gomes T, Patorno E. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Diabetes Obes Metab 2021;23:2320-8. [PMID: 34169619 DOI: 10.1111/dom.14474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 71 |
Zhao XY, Zhang F, Pan W, Yang YF, Jiang XY. Clinical potentials of ginseng polysaccharide for treating gestational diabetes mellitus. World J Clin Cases 2021; 9(19): 4959-4968 [PMID: 34307546 DOI: 10.12998/wjcc.v9.i19.4959] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 72 |
de Hoogh IM, Oosterman JE, Otten W, Krijger AM, Berbée-Zadelaar S, Pasman WJ, van Ommen B, Pijl H, Wopereis S. The Effect of a Lifestyle Intervention on Type 2 Diabetes Pathophysiology and Remission: The Stevenshof Pilot Study. Nutrients 2021;13:2193. [PMID: 34202194 DOI: 10.3390/nu13072193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Vos RC, den Ouden H, Daamen LA, Bilo HJG, Denig P, Rutten GEHM. Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years. BMJ Open Diabetes Res Care 2020;8:e000949. [PMID: 32238363 DOI: 10.1136/bmjdrc-2019-000949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 74 |
Brown A, Dornhorst A, McGowan B, Omar O, Leeds AR, Taheri S, Frost GS. Low-energy total diet replacement intervention in patients with type 2 diabetes mellitus and obesity treated with insulin: a randomized trial. BMJ Open Diabetes Res Care 2020;8:e001012. [PMID: 32049634 DOI: 10.1136/bmjdrc-2019-001012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 75 |
Juray S, Axen KV, Trasino SE. Remission of Type 2 Diabetes with Very Low-Calorie Diets-A Narrative Review. Nutrients 2021;13:2086. [PMID: 34207117 DOI: 10.3390/nu13062086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 76 |
Nielsen J, Cunningham SA, Ali MK, Patel SA. Spouse's Diabetes Status and Incidence of Depression and Anxiety: An 18-Year Prospective Study. Diabetes Care 2021;44:1264-72. [PMID: 33863752 DOI: 10.2337/dc20-2652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 77 |
Praveen EP, Chouhan S, Sahoo J, Khadgawat R, Khurana ML, Gupta N, Dwivedi SN, Kulshreshtha B. Changes in β-Cell Function in Offspring of Type-2 Diabetic Patients, as per Fasting and Two-Hour Plasma Glucose Levels. Cureus 2021;13:e15056. [PMID: 34017668 DOI: 10.7759/cureus.15056] [Reference Citation Analysis]
|
| 78 |
Gillani SMR, Raghavan R, Singh BM. A 5-year assessment of the epidemiology and natural history of possible diabetes in remission. Prim Care Diabetes 2021;15:688-92. [PMID: 33967016 DOI: 10.1016/j.pcd.2021.04.007] [Reference Citation Analysis]
|
| 79 |
Luo XM, Yan C, Feng YM. Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis. Adv Drug Deliv Rev 2021;172:234-48. [PMID: 33417981 DOI: 10.1016/j.addr.2021.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 80 |
Kalayci Z, Kamarli Altun H. ARALIKLI AÇLIK DİYETLERİNİN GLUKOZ HOMEOSTAZI VE LİPİT METABOLİZMASI ÜZERİNE ETKİLERİ. Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi 2021. [DOI: 10.46413/boneyusbad.874087] [Reference Citation Analysis]
|
| 81 |
Shin Y, Choi H, Lim S. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Diabetes Res Clin Pract 2021;175:108843. [PMID: 33933498 DOI: 10.1016/j.diabres.2021.108843] [Reference Citation Analysis]
|
| 82 |
Ding Y, Zhang H, Li C, Zheng W, Wang M, Li Y, Sun H, Wu M. Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects. Expert Opin Drug Metab Toxicol 2021;17:725-31. [PMID: 33899649 DOI: 10.1080/17425255.2021.1915283] [Reference Citation Analysis]
|
| 83 |
Evans M, Morgan AR, Bain SC. One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Ther 2021;12:1593-604. [PMID: 33899150 DOI: 10.1007/s13300-021-01061-7] [Reference Citation Analysis]
|
| 84 |
Kress S, Borck A, Zisman A, Bramlage P, Siegmund T. A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose. Diabetes Metab Syndr Obes 2021;14:1215-22. [PMID: 33776458 DOI: 10.2147/DMSO.S267882] [Reference Citation Analysis]
|
| 85 |
Moradi G, Shokri A, Mohamadi-Bolbanabad A, Zareie B, Piroozi B. Evaluating the quality of care for patients with type 2 diabetes mellitus based on the HbA1c: A national survey in Iran. Heliyon 2021;7:e06485. [PMID: 33768178 DOI: 10.1016/j.heliyon.2021.e06485] [Reference Citation Analysis]
|
| 86 |
Wheeler SE, Struebing T, Drury RLC, Caruso L, Teng BQ, Brazauskas R, Hanson RJ, Crotty BH. Glycemic relapse in a collaborative primary care-based type 2 diabetes management program. J Am Pharm Assoc (2003) 2021;61:476-483.e3. [PMID: 33715974 DOI: 10.1016/j.japh.2021.02.007] [Reference Citation Analysis]
|
| 87 |
Ali SM, Chen P, Sheikh S, Ahmad A, Ahmad M, Paithankar M, Desai B, Patel P, Khan M, Chaturvedi A, Patel R, Panchal DT, Shah K, Chavda V, Saboo BD, Patel A, Ahmad I. Thymoquinone with Metformin Decreases Fasting, Post Prandial Glucose, and HbA1c in Type 2 Diabetic Patients. Drug Res (Stuttg) 2021;71:302-6. [PMID: 33684953 DOI: 10.1055/a-1388-5415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 88 |
Liu JJ, Gurung RL, Liu S, Yiamunaa M, Lee J, Ang K, Tavintharan S, Tang WE, Sum CF, Lim SC. Associations of young onset age and genetic risk of beta cell dysfunction with glycaemic progression in individuals with type 2 diabetes. Diabetes Metab 2021;47:101238. [PMID: 33636360 DOI: 10.1016/j.diabet.2021.101238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 89 |
Yen FS, Wei JC, Lin MC, Hsu CC, Hwu CM. Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes. BMC Endocr Disord 2021;21:25. [PMID: 33602190 DOI: 10.1186/s12902-021-00690-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 90 |
Breukelman GJ, Basson AK, Djarova TG, Shaw BS, du Preez CJ, Shaw I. Establishing a proof of concept for the effects of low-carbohydrate, high-fat diet (LCHFD) and physical activity on body composition in type 2 diabetes. Heliyon 2021;7:e06266. [PMID: 33665433 DOI: 10.1016/j.heliyon.2021.e06266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 91 |
Islam SMS, Ahmed S, Uddin R, Siddiqui MU, Malekahmadi M, Al Mamun A, Alizadehsani R, Khosravi A, Nahavandi S. Cardiovascular diseases risk prediction in patients with diabetes: Posthoc analysis from a matched case-control study in Bangladesh. J Diabetes Metab Disord 2021;20:417-25. [PMID: 34222069 DOI: 10.1007/s40200-021-00761-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 92 |
Christensen MB, Serifovski N, Herz AM, Schmidt S, Hommel E, Raimond L, Perrild H, Gotfredsen A, Gæde P, Nørgaard K. Efficacy of Bolus Calculation and Advanced Carbohydrate Counting in Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Technology & Therapeutics 2021;23:95-103. [DOI: 10.1089/dia.2020.0276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 93 |
Yang M, Darwish T, Larraufie P, Rimmington D, Cimino I, Goldspink DA, Jenkins B, Koulman A, Brighton CA, Ma M, Lam BYH, Coll AP, O'Rahilly S, Reimann F, Gribble FM. Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells. Sci Rep 2021;11:2529. [PMID: 33510216 DOI: 10.1038/s41598-021-81349-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 94 |
Ji L, Li L, Ma J, Li X, Li D, Meng B, Lu W, Sun J, Liu Y, Takayanagi G, Wang Y. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study. Endocrinol Diabetes Metab 2021;4:e00222. [PMID: 33855222 DOI: 10.1002/edm2.222] [Reference Citation Analysis]
|
| 95 |
Lefever E, Vliebergh J, Mathieu C. Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. Expert Opin Drug Saf 2021;20:155-69. [PMID: 33249944 DOI: 10.1080/14740338.2021.1856813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 96 |
Joaqui VB, Gómez NB, Ortiz RC, Toro LMO, Lombo JPM, Cifuentes CAS, García MAM, Lomba AA. Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia. Archives of Endocrinology and Metabolism 2021. [DOI: 10.20945/2359-3997000000319] [Reference Citation Analysis]
|
| 97 |
Wu J, Morrison F, Zhao Z, Haynes G, He X, Ali AK, Shubina M, Malmasi S, Ge W, Peng X, Turchin A. Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study. Clin Diabetes Endocrinol 2021;7:1. [PMID: 33402226 DOI: 10.1186/s40842-020-00115-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 98 |
Ampudia-Blasco FJ, Palanca A, Trillo JL, Navarro J, Real JT. Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. J Diabetes Complications 2021;35:107828. [PMID: 33436143 DOI: 10.1016/j.jdiacomp.2020.107828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 99 |
Huang H, Lorenz BR, Zelmanovitz PH, Chan CB. Metformin Preserves β-Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats. Int J Mol Sci 2021;22:E421. [PMID: 33401592 DOI: 10.3390/ijms22010421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 100 |
Misra P, Chakrabarti R. Type 2 Diabetes Mellitus: Marketed Drugs and Mechanisms. Drug Discovery and Drug Development 2021. [DOI: 10.1007/978-981-15-8002-4_7] [Reference Citation Analysis]
|
| 101 |
Selim S, Nabi M, Saifuddin M, Hannan MA, Bakar MA, Talukder SK, Hasan ABMK, Amin MN, Hoque MA, Rahman MS, Mir AS, Afsana F. Demographic, Clinical and Biochemical Characteristics of Drug Naive Type 2 Diabetes Patients of Bangladesh. OJEMD 2021;11:145-154. [DOI: 10.4236/ojemd.2021.118012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 102 |
Zalan A, Sharkia R. Type 2 Diabetes Mellitus (T2DM) in the Arab Society of Israel. Handbook of Healthcare in the Arab World 2021. [DOI: 10.1007/978-3-030-36811-1_162] [Reference Citation Analysis]
|
| 103 |
Uphaus T, Gröschel K. Schlaganfall – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. Springer Reference Pflege – Therapie – Gesundheit 2021. [DOI: 10.1007/978-3-662-62426-5_43] [Reference Citation Analysis]
|
| 104 |
Rao VP, Rizzo MA. Diffusion of metabolites across gap junctions mediates metabolic coordination of β-islet cells.. [DOI: 10.1101/2020.12.23.424180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 105 |
Jude EB, Trescoli C, Emral R, Ali A, Lubwama R, Palmer K, Shaunik A, Nanda N, Raskin P, Gomez-Peralta F. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study. Diabetes Obes Metab 2021;23:929-37. [PMID: 33319424 DOI: 10.1111/dom.14298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 106 |
Lautsch D, Alsumali A, McLeod E, Kuang Y, He J, Singh R, Nevo A, Arnet U, Uyei J, Rajpathak S. Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. Diabetes Ther 2021;12:389-418. [PMID: 33313996 DOI: 10.1007/s13300-020-00975-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 107 |
Jung I, Kwon H, Park SE, Han KD, Park YG, Kim YH, Rhee EJ, Lee WY. Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study. Diabetes Metab J 2021;45:379-89. [PMID: 33297602 DOI: 10.4093/dmj.2020.0008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 108 |
Zhao J, Yang S, Shu B, Chen L, Yang R, Xu Y, Xie J, Liu X, Qi S. Transient High Glucose Causes Persistent Vascular Dysfunction and Delayed Wound Healing by the DNMT1-Mediated Ang-1/NF-κB Pathway. J Invest Dermatol 2021;141:1573-84. [PMID: 33259831 DOI: 10.1016/j.jid.2020.10.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 109 |
De Buitléir C, O' Connor E, Satti MM, Shaw J, Liew A. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials. Diabet Med 2021;38:e14409. [PMID: 32979231 DOI: 10.1111/dme.14409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 110 |
Ahmad E, Sargeant JA, Zaccardi F, Khunti K, Webb DR, Davies MJ. Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes? Pharmaceuticals (Basel) 2020;13:E427. [PMID: 33261058 DOI: 10.3390/ph13120427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 111 |
St. Clair JR, Westacott MJ, Farnsworth NL, Kravets V, Schleicher WE, Miranda J, Heintz A, Ludin NW, Benninger RK. Restoring Connexin-36 Function in Diabetogenic Environments Precludes Mouse and Human Islet Dysfunction.. [DOI: 10.1101/2020.11.03.366179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 112 |
Sadeghi H, Monazah E, Tavan A, Yousefzadeh G, Naderi M, Sadeghi A, Sedri N. Investigating the relationship between myocardial infarction and the ratio of glycated albumin to glycated hemoglobin in patients admitted to cardiac ward. Int J Diabetes Dev Ctries 2021;41:307-13. [DOI: 10.1007/s13410-020-00883-8] [Reference Citation Analysis]
|
| 113 |
Masierek M, Nabrdalik K, Kwiendacz H, Sawczyn T, Gumprecht J. A Multicenter, Prospective, Observational, Open-Label Study of the Safety and Comfort of Gensulin® Delivery Device Use in a Large Cohort of Adult and Elderly Patients with Type 2 Diabetes. Int J Environ Res Public Health 2020;17:E7587. [PMID: 33086494 DOI: 10.3390/ijerph17207587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 114 |
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102. [PMID: 33068776 DOI: 10.1016/j.molmet.2020.101102] [Cited by in Crossref: 156] [Cited by in F6Publishing: 174] [Article Influence: 52.0] [Reference Citation Analysis]
|
| 115 |
Chen CC, Li TC, Huang CY, Chang MP. Validation of the Chinese version of the insulin treatment appraisal scale. Diabetes Res Clin Pract 2020;170:108485. [PMID: 33035596 DOI: 10.1016/j.diabres.2020.108485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 116 |
Pan Z, Yang Y, Zhang J. Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes. J Diabetes 2020. [PMID: 33016503 DOI: 10.1111/1753-0407.13119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 117 |
Zheng H, Toupin-April K, An Y, He S, Sigal RJ, Coyle D, Wells GA, Li G. Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. Diabetes Res Clin Pract 2020;170:108471. [PMID: 33002550 DOI: 10.1016/j.diabres.2020.108471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 118 |
Ejlali N, Pezeshk H, Chaubey YP, Sadeghi M, Ebrahimi A, Nowzari-dalini A. Parrondo’s paradox for games with three players and its potential application in combination therapy for type II diabetes. Physica A: Statistical Mechanics and its Applications 2020;556:124707. [DOI: 10.1016/j.physa.2020.124707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 119 |
Lim S, Ku EJ, Lee SY, Lee JH, Lee JE, Kim KM, Davies MJ. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Res Care 2020;8:e000807. [PMID: 31958303 DOI: 10.1136/bmjdrc-2019-000807] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 120 |
van den Heuvel JM, Farzan N, van Hoek M, Maitland-van der Zee AH, Ahmadizar F. Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands. BMJ Open Diabetes Res Care 2020;8:e000767. [PMID: 31958296 DOI: 10.1136/bmjdrc-2019-000767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 121 |
Naser AY, Alsairafi Z, Alwafi H, Mohammad Turkistani F, Saud Bokhari N, Alenazi B, Zmaily Dahmash E, Alyami HS. The perspectives of physicians regarding antidiabetic therapy de-intensification and factors affecting their treatment choices-A cross-sectional study. Int J Clin Pract 2021;75:e13662. [PMID: 32770843 DOI: 10.1111/ijcp.13662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 122 |
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci 2020;21:E6275. [PMID: 32872570 DOI: 10.3390/ijms21176275] [Cited by in Crossref: 278] [Cited by in F6Publishing: 311] [Article Influence: 92.7] [Reference Citation Analysis]
|
| 123 |
Molocea CE, Tsokanos FF, Herzig S. Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. Curr Opin Pharmacol 2020;53:101-16. [PMID: 32871469 DOI: 10.1016/j.coph.2020.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 124 |
Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. Front Endocrinol (Lausanne) 2020;11:568. [PMID: 32982969 DOI: 10.3389/fendo.2020.00568] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 125 |
Masulli M, Della Pepa G, Cocozza S, Capasso M, Pignataro P, Vitale M, Gastaldelli A, Russo M, Dolce P, Riccardi G, Rivellese AA, Vaccaro O. The Pro12Ala polymorphism of PPARγ2 modulates beta cell function and failure to oral glucose-lowering drugs in patients with type 2 diabetes. Diabetes Metab Res Rev 2021;37:e3392. [PMID: 32783395 DOI: 10.1002/dmrr.3392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 126 |
Mehta R, Chen R, Hirose T, John M, Kok A, Lehmann R, Unnikrishnan AG, Yavuz DG, Fulcher G. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes Obes Metab 2020;22:1961-75. [PMID: 32618405 DOI: 10.1111/dom.14128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 127 |
Cunningham SM, Tanner DA. A Review: The Prospect of Inhaled Insulin Therapy via Vibrating Mesh Technology to Treat Diabetes. Int J Environ Res Public Health 2020;17:E5795. [PMID: 32785196 DOI: 10.3390/ijerph17165795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 128 |
Sugama H, Matsudaira T, Yanagisawa H, Ohashi R, Nawano M, Yasuda K, Takayama H. Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators. Bioorg Med Chem Lett 2020;30:127249. [PMID: 32527453 DOI: 10.1016/j.bmcl.2020.127249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 129 |
Lane WS, Favaro E, Rathor N, Jang HC, Kjærsgaard MIS, Oviedo A, Rose L, Senior P, Sesti G, Soto Gonzalez A, Franek E. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Diabetes Care 2020;43:1710-6. [PMID: 32209647 DOI: 10.2337/dc19-2232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 130 |
Martín-Peláez S, Fito M, Castaner O. Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. Nutrients 2020;12:E2236. [PMID: 32726990 DOI: 10.3390/nu12082236] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 18.7] [Reference Citation Analysis]
|
| 131 |
Agbaje OF, Coleman RL, Hattersley AT, Jones AG, Pearson ER, Shields BM, Holman RR; MASTERMIND consortium. Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87). Diabetes Res Clin Pract 2020;166:108333. [PMID: 32702468 DOI: 10.1016/j.diabres.2020.108333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 132 |
Chen L, Ma W, Tang W, Zha P, Wang C, Chen D, Lei F, Li T, Tang X, Ran X. Prevalence of Obstructive Sleep Apnea in Patients With Diabetic Foot Ulcers. Front Endocrinol (Lausanne) 2020;11:416. [PMID: 32760345 DOI: 10.3389/fendo.2020.00416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 133 |
Kapeluto JE, Tchernof A, Masckauchan D, Biron S, Marceau S, Hould FS, Lebel S, Lescelleur O, Julien F, Biertho L. Ten-year remission rates in insulin-treated type 2 diabetes after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis 2020;16:1701-12. [PMID: 32800734 DOI: 10.1016/j.soard.2020.06.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 134 |
Rigato M, Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2020;105:dgaa178. [PMID: 32271381 DOI: 10.1210/clinem/dgaa178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 135 |
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S. Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis. Diabetes Ther 2020;11:1745-55. [PMID: 32562244 DOI: 10.1007/s13300-020-00857-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 136 |
Rajpal A, Ismail-Beigi F. Intermittent fasting and 'metabolic switch': Effects on metabolic syndrome, prediabetes and type 2 diabetes. Diabetes Obes Metab 2020;22:1496-510. [PMID: 32372521 DOI: 10.1111/dom.14080] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 137 |
Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, Amona RA, El Nahas K, Suleiman N, Alnaama A, Al-Hamaq A, Charlson M, Wells MT, Al-Abdulla S, Abou-Samra AB. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2020;8:477-89. [PMID: 32445735 DOI: 10.1016/S2213-8587(20)30117-0] [Cited by in Crossref: 122] [Cited by in F6Publishing: 99] [Article Influence: 40.7] [Reference Citation Analysis]
|
| 138 |
Gómez-Banoy N, Lo JC. Adipokines as key players in β cell function and failure. Clin Sci (Lond) 2019;133:2317-27. [PMID: 31769478 DOI: 10.1042/CS20190523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 139 |
Umpierrez GE, Holt EH, Einhorn D, McGill JB. CONCENTRATED INSULINS: CLINICAL UPDATE OF THERAPEUTIC OPTIONS. Endocr Pract 2020;26:1-12. [PMID: 32339033 DOI: 10.4158/EP-2019-0607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 140 |
Zhao J, Yang S, Chen L, Yang R, Xu Y, Xie J, Liu X, Shu B, Qi S. Transient high glucose causes delayed wound healing by the DNMT1-mediated Ang-1/NF-κB pathway.. [DOI: 10.1101/2020.04.27.063198] [Reference Citation Analysis]
|
| 141 |
Rajput MA, Ali F, Zehra T, Zafar S, Kumar G. The effect of proton pump inhibitors on glycaemic control in diabetic patients. J Taibah Univ Med Sci 2020;15:218-23. [PMID: 32647517 DOI: 10.1016/j.jtumed.2020.03.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 142 |
Babaei Khorzoughi R, Namvarjah F, Teimouri M, Hosseini H, Meshkani R. In-vitro Synergistic Effect of Metformin and Berberine on High Glucose-induced Lipogenesis. Iran J Pharm Res 2019;18:1921-30. [PMID: 32184858 DOI: 10.22037/ijpr.2019.15085.12867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 143 |
Chaveepojnkamjorn W, Boorasri W, Viwatwongkasem C, Siri S, Krienkaisakda W. Association between hemoglobin A1c and acute ischemic stroke among patients with type-2 diabetes: a case-control study. Int J Diabetes Dev Ctries 2020;40:555-60. [DOI: 10.1007/s13410-020-00806-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 144 |
Athanasakis K, Prodromiadou E, Papazafiropoulou A, Koutsovasilis A, Driva S, Ziori M, Georgopoulos E, Gougourelas D, Sotiropoulos A, Bousboulas S, Melidonis A, Liatis S. Twenty-year trends in the prescription costs of Type 2 diabetes: Real world data and empirical analysis in Greece. Diabetes Res Clin Pract. 2020;162:108095. [PMID: 32112790 DOI: 10.1016/j.diabres.2020.108095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 145 |
Sugiyama S, Jinnouchi H, Hieshima K, Kurinami N, Jinnouchi K. Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor. Cureus 2020;12:e7110. [PMID: 32175210 DOI: 10.7759/cureus.7110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 146 |
Turchin A, Hosomura N, Zhang H, Malmasi S, Shubina M. Predictors and consequences of declining insulin therapy by individuals with type 2 diabetes. Diabet Med 2020;37:814-21. [DOI: 10.1111/dme.14260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 147 |
Asare-Bediako B, Noothi SK, Li Calzi S, Athmanathan B, Vieira CP, Adu-Agyeiwaah Y, Dupont M, Jones BA, Wang XX, Chakraborty D, Levi M, Nagareddy PR, Grant MB. Characterizing the Retinal Phenotype in the High-Fat Diet and Western Diet Mouse Models of Prediabetes. Cells 2020;9:E464. [PMID: 32085589 DOI: 10.3390/cells9020464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 148 |
Jeihooni AK, Khiyali Z, Faghih F, Harsini PA, Rahbar M. The Effect of Educational Program Based on the Extended Theory of Reasoned Action on Self-Care Behaviors in Women with Type 2 Diabetes. Indian J Endocrinol Metab 2019;23:609-15. [PMID: 32042696 DOI: 10.4103/ijem.IJEM_439_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 149 |
England CY, Andrews RC. James Lind Alliance research priorities: should diet and exercise be used as an alternative to drugs for the management of type 2 diabetes or alongside them? Diabet Med 2020;37:564-72. [DOI: 10.1111/dme.14217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Sukkar L, Young T, Jardine MJ. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents? Kidney Blood Press Res 2020;45:823-836. [DOI: 10.1159/000511214] [Reference Citation Analysis]
|
| 151 |
Ringelstein EB. Primärprävention und Sekundärprävention des Hirninfarkts. Klinische Neurologie 2020. [DOI: 10.1007/978-3-662-60676-6_149] [Reference Citation Analysis]
|
| 152 |
Kshirsagar RP, Kulkarni AA, Chouthe RS, Pathan SK, Une HD, Reddy GB, Diwan PV, Ansari SA, Sangshetti JN. SGLT inhibitors as antidiabetic agents: a comprehensive review. RSC Adv 2020;10:1733-56. [DOI: 10.1039/c9ra08706k] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 153 |
Durrer C, McKelvey S, Singer J, Batterham AM, Johnson JD, Wortman J, Little JP. Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol. Trials 2019;20:781. [PMID: 31881991 DOI: 10.1186/s13063-019-3873-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 154 |
Sivalingam VN, Latif A, Kitson S, McVey R, Finegan KG, Marshall K, Lisanti MP, Sotgia F, Stratford IJ, Crosbie EJ. Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. Br J Cancer 2020;122:62-71. [PMID: 31819173 DOI: 10.1038/s41416-019-0627-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 155 |
Gagnon ME, Sirois C, Simard M, Plante C. Polypharmacy and Pharmacological Treatment of Diabetes in Older Individuals: A Population-Based Study in Quebec, Canada. Pharmacy (Basel) 2019;7:E161. [PMID: 31805662 DOI: 10.3390/pharmacy7040161] [Reference Citation Analysis]
|
| 156 |
Upsher R, Allen-Taylor M, Reece I, Chamley M, Ismail K, Forbes A, Winkley K. Experiences of Attending Group Education to Support Insulin Initiation in Type 2 Diabetes: A Qualitative Study. Diabetes Ther 2020;11:119-32. [PMID: 31732858 DOI: 10.1007/s13300-019-00727-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 157 |
Bolevich S, Milosavljevic I, Draginic N, Andjic M, Jeremic N, Bolevich S, Litvitsky PF, Jakovljevic V. The Effect of the Chronic Administration of DPP4-Inhibitors on Systemic Oxidative Stress in Rats with Diabetes Type 2. Serbian Journal of Experimental and Clinical Research 2019;20:199-206. [DOI: 10.2478/sjecr-2019-0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 158 |
Gómez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, Putzel G, Rosselot C, Pabón MA, Camporez JP, Bhambhani V, Hwang SJ, Yao C, Perry RJ, Mukherjee S, Larson MG, Levy D, Dow LE, Shulman GI, Dephoure N, Garcia-Ocana A, Hao M, Spiegelman BM, Ho JE, Lo JC. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med 2019;25:1739-47. [PMID: 31700183 DOI: 10.1038/s41591-019-0610-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 159 |
Chawla R, Makkar BM, Aggarwal S, Bajaj S, Das AK, Ghosh S, Gupta A, Gupta S, Jaggi S, Jana J, Keswadev J, Kalra S, Keswani P, Kumar V, Maheshwari A, Moses A, Nawal CL, Panda J, Panikar V, Ramchandani GD, Rao PV, Saboo B, Sahay R, Setty KR, Viswanathan V, Aravind S, Banarjee S, Bhansali A, Chandalia H, Das S, Gupta O, Joshi S, Kumar A, Kumar K, Madhu S, Mittal A, Mohan V, Munichhoodappa C, Ramachandran A, Sahay B, Sai J, Seshiah V, Zargar A; Expert panel (extended). RSSDI consensus recommendations on insulin therapy in the management of diabetes. Int J Diabetes Dev Ctries 2019;39:43-92. [DOI: 10.1007/s13410-019-00783-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 160 |
Florez L, Shubina M, Turchin A. Predictors of glycemic control after decline of insulin therapy by patients with type 2 diabetes. Journal of Diabetes and its Complications 2019;33:107418. [DOI: 10.1016/j.jdiacomp.2019.107418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 161 |
Wexler DJ, Krause-Steinrauf H, Crandall JP, Florez HJ, Hox SH, Kuhn A, Sood A, Underkofler C, Aroda VR; GRADE Research Group. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2019;42:2098-107. [PMID: 31391203 DOI: 10.2337/dc19-0901] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 162 |
Fiorentino TV, Casiraghi F, Davalli AM, Finzi G, La Rosa S, Higgins PB, Abrahamian GA, Marando A, Sessa F, Perego C, Guardado-Mendoza R, Kamath S, Ricotti A, Fiorina P, Daniele G, Paez AM, Andreozzi F, Bastarrachea RA, Comuzzie AG, Gastaldelli A, Chavez AO, Di Cairano ES, Frost P, Luzi L, Dick EJ, Halff GA, DeFronzo RA, Folli F. Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas. JCI Insight 2019;4:93091. [PMID: 31536476 DOI: 10.1172/jci.insight.93091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 163 |
Abramson A, Caffarel-Salvador E, Soares V, Minahan D, Tian RY, Lu X, Dellal D, Gao Y, Kim S, Wainer J, Collins J, Tamang S, Hayward A, Yoshitake T, Lee HC, Fujimoto J, Fels J, Frederiksen MR, Rahbek U, Roxhed N, Langer R, Traverso G. A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat Med 2019;25:1512-8. [PMID: 31591601 DOI: 10.1038/s41591-019-0598-9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 164 |
Demoz GT, Berha AB, Alebachew Woldu M, Yifter H, Shibeshi W, Engidawork E. Drug therapy problems, medication adherence and treatment satisfaction among diabetic patients on follow-up care at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. PLoS One 2019;14:e0222985. [PMID: 31574113 DOI: 10.1371/journal.pone.0222985] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 165 |
Senior P, Hramiak I. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. Canadian Journal of Diabetes 2019;43:515-23. [DOI: 10.1016/j.jcjd.2019.01.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 166 |
Wattamwar T, Mungantiwar A, Halde S, Pandita N. Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography–mass spectrometry and application to pharmacokinetics. Eur J Mass Spectrom (Chichester) 2020;26:117-30. [DOI: 10.1177/1469066719879297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 167 |
Can Ö, Kısıoğlu SV, Tekin S, Sargın M. Sitagliptin Add-on to Metformin Therapy: The Efficacy of Dual Therapy on Glycemic Control in Type 2 Diabetes. Ankara Medical Journal 2019. [DOI: 10.17098/amj.624529] [Reference Citation Analysis]
|
| 168 |
Wang K, Chen Y, Strizek A, Boye K, Gu L, Liu Y, Qu S. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis. Clin Ther 2019;41:2057-65. [PMID: 31514971 DOI: 10.1016/j.clinthera.2019.08.003] [Reference Citation Analysis]
|
| 169 |
Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019;7:726-36. [PMID: 31097391 DOI: 10.1016/S2213-8587(19)30076-2] [Cited by in Crossref: 118] [Cited by in F6Publishing: 98] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 170 |
Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab 2020;22:107-15. [PMID: 31469217 DOI: 10.1111/dom.13871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 171 |
Kondratyeva LV. Early combination therapy for type 2 diabetes. Time for new decisions. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-12-115-121] [Reference Citation Analysis]
|
| 172 |
Tsilingiris D, Koliaki C, Kokkinos A. Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction? Int J Environ Res Public Health 2019;16:E3171. [PMID: 31480306 DOI: 10.3390/ijerph16173171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 173 |
Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55. [PMID: 31470636 DOI: 10.3390/medicina55090546] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 19.3] [Reference Citation Analysis]
|
| 174 |
Lu J, Guo M, Wang H, Pan H, Wang L, Yu X, Zhang X. Association between Pancreatic Atrophy and Loss of Insulin Secretory Capacity in Patients with Type 2 Diabetes Mellitus. J Diabetes Res 2019;2019:6371231. [PMID: 31467928 DOI: 10.1155/2019/6371231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 175 |
Zang L, Han Y, Chen L, Hu D, Jin H, Yang N, Shi X, Liang L, Liu M, Fan H, Li Q, Mu Y. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study. Diabetes Ther 2019;10:1391-405. [PMID: 31222594 DOI: 10.1007/s13300-019-0645-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 176 |
Basterra-Gortari FJ, Ruiz-Canela M, Martínez-González MA, Babio N, Sorlí JV, Fito M, Ros E, Gómez-Gracia E, Fiol M, Lapetra J, Estruch R, Serra-Majem L, Pinto X, González JI, Bulló M, Castañer O, Alonso-Gómez Á, Forga L, Arós F; PREDIMED Study Investigators. Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. Diabetes Care 2019;42:1390-7. [PMID: 31182491 DOI: 10.2337/dc18-2475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 177 |
Hu J, Yang C, Wang H, Li J, Tan X, Wang J, Zhang B, Zhao Y. An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother 2019;20:1679-87. [PMID: 31335214 DOI: 10.1080/14656566.2019.1645124] [Reference Citation Analysis]
|
| 178 |
Yu HM, Kim SJ, Chun SW, Park KY, Lim DM, Lee JM, Hong JH, Park KS. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. Diabetes Res Clin Pract 2019;155:107796. [PMID: 31326458 DOI: 10.1016/j.diabres.2019.107796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 179 |
Bruce DG, Davis TME, Davis WA. Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study. Acta Diabetol 2019;56:767-76. [PMID: 30945048 DOI: 10.1007/s00592-019-01322-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 180 |
Ried-Larsen M, Johansen MY, MacDonald CS, Hansen KB, Christensen R, Wedell-Neergaard AS, Pilmark NS, Langberg H, Vaag AA, Pedersen BK, Karstoft K. Type 2 diabetes remission 1 year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial. Diabetes Obes Metab 2019;21:2257-66. [PMID: 31168922 DOI: 10.1111/dom.13802] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 181 |
Kassab BM, Hussein HH, Mahmoud OM, Abdel-Alrahman G. Effects of insulin and metformin on fetal kidney development of streptozotocin-induced gestational diabetic albino rats. Anat Cell Biol 2019;52:161-75. [PMID: 31338233 DOI: 10.5115/acb.2019.52.2.161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 182 |
H. I SS, Moodithaya S, Sharma R, Mirajkar AM. METABOLIC AND CARDIOVASCULAR PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS UNDERGOING DIFFERENT TREATMENT MODALITIES. jemds 2019;8:1921-1925. [DOI: 10.14260/jemds/2019/422] [Reference Citation Analysis]
|
| 183 |
Ji L, Chen L, Wang Y, Ma Z, Ran X, Sun Z, Xu X, Wang G, Guo L, Shan Z. Study Protocol for a Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of a Needle-Free Insulin Injector and a Conventional Insulin Pen in Controlling Blood Glucose Concentrations in Chinese Patients with Type 2 Diabetes Mellitus (The FREE Study). Adv Ther 2019;36:1485-96. [PMID: 31004325 DOI: 10.1007/s12325-019-00951-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 184 |
Alharbi AA, Shaqran TM, Eltobgy AAE, Albalawi AR, Alnawmasi WS. Physicians' Perspective on Diabetes Mellitus Management within the Context of Personalized Medicine Era in Tabuk Governorate, Saudi Arabia. Open Access Maced J Med Sci 2019;7:1706-11. [PMID: 31210827 DOI: 10.3889/oamjms.2019.322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 185 |
Xie J, Li N, Jiang X, Chai L, Chen JJ, Deng W. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2019;12:519-26. [PMID: 31114280 DOI: 10.2147/DMSO.S198154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 186 |
Rodríguez-sánchez B, Feenstra TL, Bilo HJG, Alessie RJM. Costs of people with diabetes in relation to average glucose control: an empirical approach controlling for year of onset cohorts. Eur J Health Econ 2019;20:989-1000. [DOI: 10.1007/s10198-019-01072-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 187 |
Donnan JR, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, Nguyen H, Gamble JM. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment. Can J Diabetes 2020;44:6-13. [PMID: 31311729 DOI: 10.1016/j.jcjd.2019.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Pandey J, Tamrakar AK. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). Expert Opinion on Therapeutic Patents 2019;29:369-84. [DOI: 10.1080/13543776.2019.1612879] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 189 |
Hammeso WW, Emiru YK, Ayalew Getahun K, Kahaliw W. Antidiabetic and Antihyperlipidemic Activities of the Leaf Latex Extract of Aloe megalacantha Baker (Aloaceae) in Streptozotocin-Induced Diabetic Model. Evid Based Complement Alternat Med 2019;2019:8263786. [PMID: 31178917 DOI: 10.1155/2019/8263786] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 190 |
Barengo NC, Acosta T, Arrieta A, Ricaurte C, Smits D, Florez K, Tuomilehto JO. Early Lifestyle Interventions in People with Impaired Glucose Tolerance in Northern Colombia: The DEMOJUAN Project. Int J Environ Res Public Health 2019;16:E1403. [PMID: 31003515 DOI: 10.3390/ijerph16081403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 191 |
Chen H, Nie Q, Hu J, Huang X, Zhang K, Nie S. Glucomannans Alleviated the Progression of Diabetic Kidney Disease by Improving Kidney Metabolic Disturbance. Mol Nutr Food Res 2019;63:1801008. [DOI: 10.1002/mnfr.201801008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 192 |
Yu JH, Kim HY, Kim SR, Ko E, Jin HY. Factors influencing psychological insulin resistance in type 2 diabetes patients. Int J Nurs Pract 2019;25:e12733. [DOI: 10.1111/ijn.12733] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 193 |
Tasci I, Safer U, Naharci MI. Multiple Antihyperglycemic Drug Use is Associated with Undernutrition Among Older Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study. Diabetes Ther 2019;10:1005-18. [PMID: 30924077 DOI: 10.1007/s13300-019-0602-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 194 |
Cziraky MJ, Abbott S, Nguyen M, Larholt K, Apgar E, Wasser T, Strange P, Shi L, Harrison HC, Everitt B, Nowak L. A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes. J Health Econ Outcomes Res 2019;6:70-83. [PMID: 32685581 DOI: 10.36469/9731] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 195 |
Ferraz ÁAB, de Sá VCT, Santa-Cruz F, Siqueira LT, Silva LB, Campos JM. Roux-en-Y gastric bypass for nonobese patients with uncontrolled type 2 diabetes: a long-term evaluation. Surg Obes Relat Dis 2019;15:682-7. [PMID: 31005458 DOI: 10.1016/j.soard.2019.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 196 |
Rallis S. Optimizing glycemic control in type 2 diabetic patients through the use of a low-carbohydrate, high-fat, ketogenic diet: a review of two patients in primary care. Diabetes Metab Syndr Obes 2019;12:299-303. [PMID: 30881073 DOI: 10.2147/DMSO.S195994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 197 |
Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, Liew D. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep 2019;9:3256. [PMID: 30824788 DOI: 10.1038/s41598-019-40191-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 198 |
Zhou P, Xie W, He S, Sun Y, Meng X, Sun G, Sun X. Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. Cells 2019;8:E204. [PMID: 30823412 DOI: 10.3390/cells8030204] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 199 |
Nielen JT, Dagnelie PC, Boonen A, Klungel O, van den Bemt B, de Vries F. Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. Diabetes Research and Clinical Practice 2019;148:240-8. [DOI: 10.1016/j.diabres.2019.01.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 200 |
Kaneko R, Ono S. Exploratory analysis of comparative clinical trials used for marketing approval in patients with type 2 diabetes in Japan. SAGE Open Med 2019;7:2050312118823407. [PMID: 30671243 DOI: 10.1177/2050312118823407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 201 |
Basu A, Sohn MW, Bartle B, Chan KCG, Cooper JM, Huang E. Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. Med Decis Making 2019;39:137-51. [PMID: 30654704 DOI: 10.1177/0272989X18817521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 202 |
Yang HK, Lee SH, Shin J, Choi YH, Ahn YB, Lee BW, Rhee EJ, Min KW, Yoon KH. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Metab J 2019;43:287-301. [PMID: 30604599 DOI: 10.4093/dmj.2018.0054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 203 |
Ringelstein EB. Primärprävention und Sekundärprävention des Hirninfarkts. Klinische Neurologie 2019. [DOI: 10.1007/978-3-662-44768-0_149-2] [Reference Citation Analysis]
|
| 204 |
Madsbad S, Holst JJ. Assessment of Islet Alpha- and Beta-Cell Function. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease 2019. [DOI: 10.1007/978-3-030-11748-1_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 205 |
Uphaus T, Gröschel K. Schlaganfall – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. Springer Reference Pflege – Therapie – Gesundheit 2019. [DOI: 10.1007/978-3-662-55793-8_43-1] [Reference Citation Analysis]
|
| 206 |
Tan SY, Mei Wong JL, Sim YJ, Wong SS, Mohamed Elhassan SA, Tan SH, Ling Lim GP, Rong Tay NW, Annan NC, Bhattamisra SK, Candasamy M. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:364-72. [DOI: 10.1016/j.dsx.2018.10.008] [Cited by in Crossref: 122] [Cited by in F6Publishing: 134] [Article Influence: 30.5] [Reference Citation Analysis]
|
| 207 |
Yoo WS, Kim DH, Kim HJ, Chung HK. Therapeutic Effect of Quadruple Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus Who Have Insulin Limitations. J Korean Diabetes 2019;20:117. [DOI: 10.4093/jkd.2019.20.2.117] [Reference Citation Analysis]
|
| 208 |
Abdelrahim HM, Madani AM, Mahmoud AN, El-hadiyah TM, Yousif AK. Addition of Insulin to Treatment Regimen in Type 2 Diabetes: The Significance of Age and Duration among Sudanese Diabetic Patients. PP 2019;10:456-463. [DOI: 10.4236/pp.2019.1010037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 209 |
Albarkah YA, Tourkmani AM, Bin Rsheed AM, Al Harbi TJ, Ebeid YA, Bushnag RA. Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia. J Family Med Prim Care 2019;8:1919-24. [PMID: 31334156 DOI: 10.4103/jfmpc.jfmpc_372_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 210 |
Baruah MP, Makkar BM, Ghatnatti VB, Mandal K. Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control. Indian J Endocrinol Metab 2019;23:140-9. [PMID: 31016169 DOI: 10.4103/ijem.IJEM_160_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 211 |
Zalan A, Sharkia R. Type 2 Diabetes Mellitus (T2DM) in the Arab Society of Israel. Handbook of Healthcare in the Arab World 2019. [DOI: 10.1007/978-3-319-74365-3_162-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 212 |
Shah PA, Shrivastav PS, Shah JV, George A. Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. Biomedical Chromatography 2019;33:e4453. [DOI: 10.1002/bmc.4453] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 213 |
Khaloo P, Asadi Komeleh S, Alemi H, Mansournia MA, Mohammadi A, Yadegar A, Afarideh M, Esteghamati S, Nakhjavani M, Esteghamati A. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea. J Endocrinol Invest 2019;42:851-7. [PMID: 30535871 DOI: 10.1007/s40618-018-0991-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 214 |
Gonzalez C, Monti C, Pinzon A, Monsanto H, Ejzykowicz F. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Endocrinología, Diabetes y Nutrición (English ed ) 2018;65:592-602. [DOI: 10.1016/j.endien.2018.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 215 |
Gonzalez C, Monti C, Pinzon A, Monsanto H, Ejzykowicz F. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Endocrinología, Diabetes y Nutrición 2018;65:592-602. [DOI: 10.1016/j.endinu.2018.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 216 |
Naser AY, Wong ICK, Whittlesea C, Beykloo MY, Man KKC, Lau WCY, Hyassat DA, Wei L. Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan. BMJ Open 2018;8:e024909. [PMID: 30467136 DOI: 10.1136/bmjopen-2018-024909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 217 |
Liao HW, Wu YL, Sue YM, Lee M, Ovbiagele B. Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 2019;2:e00050. [PMID: 30815577 DOI: 10.1002/edm2.50] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 218 |
Siegmund T, Borck A, Zisman A, Bramlage P, Kress S. A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value. J Clin Transl Endocrinol 2018;14:34-8. [PMID: 30416973 DOI: 10.1016/j.jcte.2018.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 219 |
Yamamoto WR, Bone RN, Sohn P, Syed F, Reissaus CA, Mosley AL, Wijeratne AB, True JD, Tong X, Kono T, Evans-Molina C. Endoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic β cell. J Biol Chem 2019;294:168-81. [PMID: 30420428 DOI: 10.1074/jbc.RA118.005683] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 220 |
Kono T, Tong X, Taleb S, Bone RN, Iida H, Lee CC, Sohn P, Gilon P, Roe MW, Evans-Molina C. Impaired Store-Operated Calcium Entry and STIM1 Loss Lead to Reduced Insulin Secretion and Increased Endoplasmic Reticulum Stress in the Diabetic β-Cell. Diabetes 2018;67:2293-304. [PMID: 30131394 DOI: 10.2337/db17-1351] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 221 |
Alvarenga MA, Komatsu WR, de Sa JR, Chacra AR, Dib SA. Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country. Diabetol Metab Syndr 2018;10:77. [PMID: 30386438 DOI: 10.1186/s13098-018-0382-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 222 |
Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, Dalal MR, DiGenio A. Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. Diabetes Spectr 2019;32:93-103. [PMID: 31168279 DOI: 10.2337/ds17-0082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 223 |
Seufert J, Fritsche A, Pscherer S, Anderten H, Borck A, Pegelow K, Bramlage P, Pfohl M. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Diabetes Obes Metab 2019;21:439-43. [PMID: 30226296 DOI: 10.1111/dom.13535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 224 |
Sarras Jr MP. Genetic and chemically-induced Zebrafish models for the study of diabetes mellitus. MOJAP 2018;5. [DOI: 10.15406/mojap.2018.05.00217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 225 |
Bellido D, Abellán P, Ruiz Palomar JM, Álvarez Sintes R, Nubiolae A, Bellido V, Romero G; Basal Lixi Study investigators. Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study. Curr Ther Res Clin Exp 2018;89:37-42. [PMID: 30455779 DOI: 10.1016/j.curtheres.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 226 |
Cho YS, Lee SH, Lim HS, Bae KS. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects. J Korean Med Sci 2018;33:e258. [PMID: 30288156 DOI: 10.3346/jkms.2018.33.e258] [Reference Citation Analysis]
|
| 227 |
Dhalwani NN, Zaccardi F, Waheed H, Mytton J, Papamargaritis D, Webb DR, Evison F, Lilford R, Davies MJ, Khunti K. Cardiovascular, cancer and mortality events after bariatric surgery in people with and without pre-existing diabetes: A nationwide study. Journal of Diabetes 2019;11:265-72. [DOI: 10.1111/1753-0407.12851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 228 |
Pandya K, Clark GJ, Lau-Cam CA. Investigation of the Role of a Supplementation with Taurine on the Effects of Hypoglycemic-Hypotensive Therapy Against Diabetes-Induced Nephrotoxicity in Rats. Adv Exp Med Biol 2017;975 Pt 1:371-400. [PMID: 28849470 DOI: 10.1007/978-94-024-1079-2_32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 229 |
Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, Hollingsworth KG, Mathers JC, Sattar N, Lean MEJ. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. Cell Metab 2018;28:547-556.e3. [PMID: 30078554 DOI: 10.1016/j.cmet.2018.07.003] [Cited by in Crossref: 179] [Cited by in F6Publishing: 161] [Article Influence: 35.8] [Reference Citation Analysis]
|
| 230 |
Cai X, Gao X, Yang W, Han X, Ji L. Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Ther 2018;9:1995-2014. [PMID: 30155646 DOI: 10.1007/s13300-018-0493-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 231 |
Zongo A, Grégoire JP, Moisan J, Guénette L. Measuring adherence to oral antidiabetic multi-drug treatment: Comparative validity of prescription claims-based adherence measures against hospitalization. Res Social Adm Pharm 2019;15:738-43. [PMID: 30253976 DOI: 10.1016/j.sapharm.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 232 |
Kim NH, Lim S, Kwak SH, Moon MK, Moon JS, Lee YH, Cho HC, Lee J, Kim SG. Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. BMJ Open 2018;8:e022448. [PMID: 30249630 DOI: 10.1136/bmjopen-2018-022448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 233 |
Levine MJ. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev 2017;13:405-23. [PMID: 27296042 DOI: 10.2174/1573399812666160613113556] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 20.4] [Reference Citation Analysis]
|
| 234 |
Ngufor C, Van Houten H, Caffo BS, Shah ND, McCoy RG. Mixed effect machine learning: A framework for predicting longitudinal change in hemoglobin A1c. J Biomed Inform 2019;89:56-67. [PMID: 30189255 DOI: 10.1016/j.jbi.2018.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 235 |
Kim KS, Kwag DS, Hwang HS, Lee ES, Bae YH. Immense Insulin Intestinal Uptake and Lymphatic Transport Using Bile Acid Conjugated Partially Uncapped Liposome. Mol Pharm 2018;15:4756-63. [PMID: 30125508 DOI: 10.1021/acs.molpharmaceut.8b00708] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 236 |
Ku EJ, Lee DH, Jeon HJ, Oh TK. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. Diabetes Obes Metab 2019;21:173-7. [PMID: 30039538 DOI: 10.1111/dom.13476] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 237 |
Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br J Clin Pharmacol 2018;84:2325-35. [PMID: 29926478 DOI: 10.1111/bcp.13688] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 238 |
Haring AP, Tong Y, Halper J, Johnson BN. Programming of Multicomponent Temporal Release Profiles in 3D Printed Polypills via Core-Shell, Multilayer, and Gradient Concentration Profiles. Adv Healthc Mater 2018;7:e1800213. [PMID: 29888441 DOI: 10.1002/adhm.201800213] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 239 |
Cho YY, Cho S. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Metabolism 2018;85:14-22. [DOI: 10.1016/j.metabol.2018.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 240 |
Wu CT, Tsai YT, Lin JG, Fu SL, Lai JN. Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study. Medicine (Baltimore) 2018;97:e11600. [PMID: 30075530 DOI: 10.1097/MD.0000000000011600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 241 |
Molina-vega M, Muñoz-garach A, Fernández-garcía JC, Tinahones FJ. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert Opinion on Drug Safety 2018;17:815-24. [DOI: 10.1080/14740338.2018.1497158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 242 |
Sankaranarayanan C, Nishanthi R, Pugalendi P. Ameliorating effect of berbamine on hepatic key enzymes of carbohydrate metabolism in high-fat diet and streptozotocin induced type 2 diabetic rats. Biomedicine & Pharmacotherapy 2018;103:539-45. [DOI: 10.1016/j.biopha.2018.04.066] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 243 |
DeFronzo RA, Lee C, Kohler S. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. Adv Ther 2018;35:1009-22. [PMID: 29949041 DOI: 10.1007/s12325-018-0724-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 244 |
Park JE, Jeong GH, Lee IK, Yoon YR, Liu KH, Gu N, Shin KH. A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients. Molecules 2018;23:E1579. [PMID: 29966242 DOI: 10.3390/molecules23071579] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 245 |
Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 2018;361:k2234. [PMID: 29898883 DOI: 10.1136/bmj.k2234] [Cited by in Crossref: 198] [Cited by in F6Publishing: 169] [Article Influence: 39.6] [Reference Citation Analysis]
|
| 246 |
Shi FH, Li H, Cui M, Zhang ZL, Gu ZC, Liu XY. Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2018;9:576. [PMID: 29915538 DOI: 10.3389/fphar.2018.00576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 247 |
Meetoo D, Wong L, Fatani T. 'Knowing where I am': self-monitoring of blood glucose in diabetes. Br J Nurs 2018;27:537-41. [PMID: 29791211 DOI: 10.12968/bjon.2018.27.10.537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 248 |
Zhou Y, Guo Z, Yan W, Wang W. Cardiovascular effects of sitagliptin - An anti-diabetes medicine. Clin Exp Pharmacol Physiol 2018;45:628-35. [DOI: 10.1111/1440-1681.12953] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 249 |
Nabrdalik K, Kwiendacz H, Sawczyn T, Tomasik A, Kukla M, Masierek M, Gumprecht J. Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study. Int J Endocrinol 2018;2018:6536178. [PMID: 29755520 DOI: 10.1155/2018/6536178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 250 |
Орехова Н, Собенин И, Митрофанов К, Сазонова М, Постнов А, Карагодин В, Орехов А. Association of heteroplasmic mutations in the mitochondrial genome with coronary heart disease. ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» 2018. [DOI: 10.25557/0031-2991.2018.01.4-10] [Reference Citation Analysis]
|
| 251 |
Vaccaro O, Masulli M, Riccardi G. Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study. Nutr Metab Cardiovasc Dis 2018;28:722-6. [PMID: 29804832 DOI: 10.1016/j.numecd.2018.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 252 |
Koothappan M, Vellai RD, Subramanian IP, Subramanian SP. Synthesis of a New Zinc-Mixed Ligand Complex and Evaluation of Its Antidiabetic Properties in High Fat Diet: Low Dose Streptozotocin Induced Diabetic Rats. Diabetes Metab J 2018;42:244-8. [PMID: 29885106 DOI: 10.4093/dmj.2018.0002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 253 |
Hu X, Zhang L, Dong Y, Dong C, Jiang J, Gao W. Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. F1000Res 2018;7:477. [PMID: 29862021 DOI: 10.12688/f1000research.13923.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 254 |
Aroor AR, Manrique-Acevedo C, DeMarco VG. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol 2018;17:59. [PMID: 29669555 DOI: 10.1186/s12933-018-0704-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 255 |
Montvida O, Shaw JE, Blonde L, Paul SK. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. Diabetes Obes Metab 2018;20:1722-31. [PMID: 29536608 DOI: 10.1111/dom.13288] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 256 |
Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ. Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes. Diabetes Ther 2018;9:1099-111. [PMID: 29644618 DOI: 10.1007/s13300-018-0421-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 257 |
Peng Y, Chang Q, Yang N, Gu S, Zhou Y, Yin L, Aa J, Wang G, Sun J. Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human. Journal of Chromatography B 2018;1081-1082:109-17. [DOI: 10.1016/j.jchromb.2018.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 258 |
Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, Khan N, Maccallum L, Shah BR, Simpson S. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Canadian Journal of Diabetes 2018;42:S88-S103. [DOI: 10.1016/j.jcjd.2017.10.034] [Cited by in Crossref: 104] [Cited by in F6Publishing: 116] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 259 |
Ordelheide AM, Hrabě de Angelis M, Häring HU, Staiger H. Pharmacogenetics of oral antidiabetic therapy. Pharmacogenomics 2018;19:577-87. [PMID: 29580198 DOI: 10.2217/pgs-2017-0195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 260 |
Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes Obes Metab 2018;20:1542-6. [PMID: 29446523 DOI: 10.1111/dom.13258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 261 |
Bailey RA, Shillington AC, Harshaw Q, Funnell MM, VanWingen J, Col N. Changing Patients' Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. Diabetes Ther 2018;9:803-14. [PMID: 29536425 DOI: 10.1007/s13300-018-0391-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 262 |
Gu T, Hong T, Zhang P, Tang S, Bi Y, Lu H, Men L, Ma D, Zhu D. Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response. Diabetes Ther 2018;9:771-87. [PMID: 29524190 DOI: 10.1007/s13300-018-0381-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 263 |
Severino P, D'Amato A, Netti L, Pucci M, De Marchis M, Palmirotta R, Volterrani M, Mancone M, Fedele F. Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels. Int J Mol Sci 2018;19:E802. [PMID: 29534462 DOI: 10.3390/ijms19030802] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 264 |
Pavlicek V. Pioglitazone oder Sulfonylharnstoffe als Add-on-Therapie zu Metformin. Diabetologe 2018;14:101-103. [DOI: 10.1007/s11428-018-0313-3] [Reference Citation Analysis]
|
| 265 |
Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017;21:1-218. [PMID: 28105986 DOI: 10.3310/hta21020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 266 |
Trautmann ME, Vora J. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. Diabet Med 2018;35:694-706. [PMID: 29478255 DOI: 10.1111/dme.13610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 267 |
Kanatsuka A, Kou S, Makino H. IAPP/amylin and β-cell failure: implication of the risk factors of type 2 diabetes. Diabetol Int 2018;9:143-57. [PMID: 30603362 DOI: 10.1007/s13340-018-0347-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 268 |
Avogaro A, Delgado E, Lingvay I. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev 2018;34:e2981. [PMID: 29320602 DOI: 10.1002/dmrr.2981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 269 |
Jeon JY, Lee SJ, Lee S, Kim SJ, Han SJ, Kim HJ, Kim DJ, Kim YS, Woo JT, Ahn KJ, Nam M, Baik SH, Park Y, Lee KW. Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program. J Diabetes Investig 2018;9:1144-52. [PMID: 29328551 DOI: 10.1111/jdi.12801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 270 |
Hirukawa H, Hashiramoto M, Tanizawa Y, Kaku K; Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti-Atherosclerosis in Japan (PREVENT-J) study group. Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes. J Diabetes Investig 2018;9:1119-27. [PMID: 29406607 DOI: 10.1111/jdi.12813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 271 |
Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, Huang ES. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med 2018;168:170-8. [PMID: 29230472 DOI: 10.7326/M17-0537] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 272 |
Woo VC, Berard LD, Bajaj HS, Ekoé J, Senior PA. Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin. Canadian Journal of Diabetes 2018;42:88-93. [DOI: 10.1016/j.jcjd.2017.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 273 |
Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, Li CH, Liao YC, Lo CP, Huang JL, Lin CH, Wu TJ. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol 2018;17:20. [PMID: 29368615 DOI: 10.1186/s12933-018-0663-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 274 |
Ringelstein EB. Primärprävention und Sekundärprävention des Hirninfarkts. Klinische Neurologie 2018. [DOI: 10.1007/978-3-662-44768-0_149-1] [Reference Citation Analysis]
|
| 275 |
Acosta T, Barengo NC, Arrieta A, Ricaurte C, Tuomilehto JO. A demonstration area for type 2 diabetes prevention in Barranquilla and Juan Mina (Colombia): Baseline characteristics of the study participants. Medicine (Baltimore) 2018;97:e9285. [PMID: 29505512 DOI: 10.1097/MD.0000000000009285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 276 |
Consoli A. Insulin Treatment. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_21] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 277 |
Rhee SY. Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association. J Korean Diabetes 2018;19:15. [DOI: 10.4093/jkd.2018.19.1.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 278 |
Consoli A. Insulin Treatment. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_21-1] [Reference Citation Analysis]
|
| 279 |
Ramos-prol A, Hervás-marín D, Rodríguez-medina B, Rubio-almanza M, Berenguer M, Moya-herraiz Á, Merino-torres JF. Intensified blood glucose treatment in diabetic patients undergoing a liver transplant: impact on graft evolution at 3 months and at 5 years. J Endocrinol Invest 2018;41:821-9. [DOI: 10.1007/s40618-017-0810-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 280 |
Gupta V, Canovatchel W, Lokesh BN, Santani R, Garodia N. Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal. Indian J Endocrinol Metab 2017;21:909-18. [PMID: 29285458 DOI: 10.4103/ijem.IJEM_85_17] [Reference Citation Analysis]
|
| 281 |
Del Prato S, Chilton R. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. Diabetes Obes Metab 2018;20:786-99. [PMID: 29171700 DOI: 10.1111/dom.13169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 282 |
Tay J, Thompson CH, Luscombe-marsh ND, Wycherley TP, Noakes M, Buckley JD, Wittert GA, Yancy WS, Brinkworth GD. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. Diabetes Obes Metab 2018;20:858-71. [DOI: 10.1111/dom.13164] [Cited by in Crossref: 104] [Cited by in F6Publishing: 110] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 283 |
Davis TME, Chubb SAP, Curtis BH, Barraclough H, Davis WA. Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. Intern Med J 2018;48:1215-21. [PMID: 29230931 DOI: 10.1111/imj.13710] [Reference Citation Analysis]
|
| 284 |
Kathe N, Shah A, Said Q, Painter JT. DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.Diabetes Ther. 2018;9:141-151. [PMID: 29236221 DOI: 10.1007/s13300-017-0353-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 285 |
Vidal-Peracho C, Tricás-Moreno JM, Lucha-López AC, Lucha-López MO, Camuñas-Pescador AC, Caverni-Muñoz A, Fanlo-Mazas P. Adherence to Mediterranean Diet Pattern among Spanish Adults Attending a Medical Centre: Nondiabetic Subjects and Type 1 and 2 Diabetic Patients. J Diabetes Res 2017;2017:5957821. [PMID: 29527536 DOI: 10.1155/2017/5957821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 286 |
Lee SF, Teh XR, Malar LS, Ong SL, James RP. The associations of illness perception with metabolic control (HbA1c) among type 2 diabetes mellitus patients in a district hospital. Int J Pharm Pract 2018;26:442-9. [PMID: 29193388 DOI: 10.1111/ijpp.12413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 287 |
Garg R. NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS. Endocr Pract 2017;23:1357-8. [PMID: 29190136 DOI: 10.4158/EP-2017-0135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 288 |
Faure S. Les insulinosécréteurs, sulfamides et glinides. Actualités Pharmaceutiques 2017;56:7-11. [DOI: 10.1016/j.actpha.2017.09.019] [Reference Citation Analysis]
|
| 289 |
Jia N, Kindracki Z, Rodriguez A. Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. Diabetes Res Clin Pract 2018;135:134-42. [PMID: 29155123 DOI: 10.1016/j.diabres.2017.10.006] [Reference Citation Analysis]
|
| 290 |
Ohde S, Deshpande GA, Yokomichi H, Takahashi O, Fukui T, Yamagata Z. HbA1c monitoring interval in patients on treatment for stable type 2 diabetes. A ten-year retrospective, open cohort study. Diabetes Res Clin Pract 2018;135:166-71. [PMID: 29155151 DOI: 10.1016/j.diabres.2017.11.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 291 |
Szwergold B. A Hypothesis: Moderate Consumption of Alcohol Contributes to Lower Prevalence of Type 2 Diabetes Due to the Scavenging of Alpha-Dicarbonyls by Dietary Polyphenols. Rejuvenation Res 2018;21:389-404. [PMID: 28891383 DOI: 10.1089/rej.2017.1974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 292 |
Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017;5:887-97. [PMID: 28917544 DOI: 10.1016/S2213-8587(17)30317-0] [Cited by in Crossref: 186] [Cited by in F6Publishing: 183] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 293 |
Meiszterics Z, Kónyi A, Hild G, Sárszegi Z, Gaszner B. Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes. Journal of Comparative Effectiveness Research 2017;6:649-57. [DOI: 10.2217/cer-2017-0011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 294 |
Grunberger G, Chen L, Rodriguez A, Tinahones FJ, Jacober SJ, Bue-Valleskey J; IMAGINE 6 Investigators. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes Obes Metab 2016;18 Suppl 2:34-42. [PMID: 27723225 DOI: 10.1111/dom.12743] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 295 |
Lee BW, Kim JH, Ko SH, Hur KY, Kim NH, Rhee SY, Kim HJ, Moon MK, Park SO, Choi KM; Committee of Clinical Practice Guideline of Korean Diabetes Association . Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Korean J Intern Med 2017;32:967-73. [PMID: 29057642 DOI: 10.3904/kjim.2017.314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 296 |
Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean J Intern Med 2017;32:947-58. [PMID: 29056038 DOI: 10.3904/kjim.2017.298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 297 |
Rhee SY, Kim HJ, Ko SH, Hur KY, Kim NH, Moon MK, Park SO, Lee BW, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association. Monotherapy in patients with type 2 diabetes mellitus. Korean J Intern Med 2017;32:959-66. [PMID: 29057643 DOI: 10.3904/kjim.2017.312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 298 |
Zanders MMJ, Haak HR, van Herk-Sukel MPP, Herings RMC, van de Poll-Franse LV, Johnson JA. Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes. Diabetes Metab 2018;44:22-9. [PMID: 29066209 DOI: 10.1016/j.diabet.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 299 |
McCoy RG, Ngufor C, Van Houten HK, Caffo B, Shah ND. Trajectories of Glycemic Change in a National Cohort of Adults With Previously Controlled Type 2 Diabetes. Med Care 2017;55:956-64. [PMID: 28922296 DOI: 10.1097/MLR.0000000000000807] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 300 |
Pinchevsky Y, Butkow N, Chirwa T, Raal F. Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. J Diabetes Res 2017;2017:9536025. [PMID: 29130053 DOI: 10.1155/2017/9536025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 301 |
Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni Z, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE. Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3. J Med Chem 2017;60:8482-514. [DOI: 10.1021/acs.jmedchem.7b00922] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 302 |
Devendar P, Yang G. Sulfur-Containing Agrochemicals. Top Curr Chem (Z) 2017;375. [DOI: 10.1007/s41061-017-0169-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 121] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 303 |
Kesavadev J, Pillai PBS, Shankar A, Krishnan G, Jothydev S. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Endocr Connect 2017;6:748-57. [PMID: 28982699 DOI: 10.1530/EC-17-0100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 304 |
Erickson ML, Jenkins NT, McCully KK. Exercise after You Eat: Hitting the Postprandial Glucose Target. Front Endocrinol (Lausanne) 2017;8:228. [PMID: 28974942 DOI: 10.3389/fendo.2017.00228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 305 |
Lotfi Z, Aboussaleh Y, Sbaibi R, Achouri I, Benguedour R. [The overweight, the obesity and the glycemic control among diabetics of the provincial reference center of diabetes (CRD), Kenitra, Morocco]. Pan Afr Med J 2017;27:189. [PMID: 28904714 DOI: 10.11604/pamj.2017.27.189.9535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 306 |
Block T, El-Osta A. Epigenetic programming, early life nutrition and the risk of metabolic disease. Atherosclerosis 2017;266:31-40. [PMID: 28950165 DOI: 10.1016/j.atherosclerosis.2017.09.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 307 |
Florez JC. The pharmacogenetics of metformin. Diabetologia 2017;60:1648-55. [PMID: 28770331 DOI: 10.1007/s00125-017-4335-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 308 |
Kaur N, Fernandez R, Sim J. Effect of Aloe vera on glycemic outcomes in patients with diabetes mellitus: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 2017;15:2300-6. [DOI: 10.11124/jbisrir-2016-002958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 309 |
Srinivasa Rao D, Venkata Ramana Murthy B, Aparna V, K S, T G. STUDY ON ASYMPTOMATIC BACTERIURIA IN ELDERLY DIABETIC WOMEN. jemds 2017;6:4793-4797. [DOI: 10.14260/jemds/2017/1039] [Reference Citation Analysis]
|
| 310 |
Kahraman S, Okawa ER, Kulkarni RN. Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes? Curr Diab Rep 2016;16:70. [PMID: 27313072 DOI: 10.1007/s11892-016-0764-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 311 |
Tan X, Cao X, Zhou M, Zou P, Hu J. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2017;26:1083-9. [PMID: 28741970 DOI: 10.1080/13543784.2017.1360274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 312 |
Erickson ML, Little JP, Gay JL, Mccully KK, Jenkins NT. Postmeal exercise blunts postprandial glucose excursions in people on metformin monotherapy. Journal of Applied Physiology 2017;123:444-50. [DOI: 10.1152/japplphysiol.00213.2017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 313 |
Emdin CA, Klarin D, Natarajan P, Florez JC, Kathiresan S, Khera AV; CARDIOGRAM Exome Consortium. Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes 2017;66:2310-5. [PMID: 28411266 DOI: 10.2337/db17-0149] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 314 |
Mata-Cases M, Franch-Nadal J, Real J, Gratacòs M, López-Simarro F, Khunti K, Mauricio D. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. Diabetes Obes Metab 2018;20:103-12. [PMID: 28656746 DOI: 10.1111/dom.13045] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 315 |
Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr 2017;9:59. [PMID: 28770011 DOI: 10.1186/s13098-017-0254-9] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 316 |
Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? Diabetes Obes Metab. 2017;19:1655-1668. [PMID: 28509408 DOI: 10.1111/dom.13009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 317 |
Banu S, Bhowmick A. Therapeutic Targets of Type 2 Diabetes: an Overview. M 2017;1. [DOI: 10.15406/mojddt.2017.01.00011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 318 |
Marcinak J, Cao C, Lee D, Ye Z. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study. Diabetes Obes Metab 2017;19:1714-21. [PMID: 28493502 DOI: 10.1111/dom.13004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 319 |
Aeimlapa R, Charoenphandhu N, Suntornsaratoon P, Wongdee K, Tiyasatkulkovit W, Kengkoom K, Krishnamra N. Insulin does not rescue cortical and trabecular bone loss in type 2 diabetic Goto-Kakizaki rats. J Physiol Sci 2018;68:531-40. [DOI: 10.1007/s12576-017-0558-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 320 |
Ioacara S, Guja C, Georgescu O, Martin S, Sirbu A, Purcaru M, Fica S. PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN. Acta Endocrinol (Buchar) 2017;13:329-33. [PMID: 31149195 DOI: 10.4183/aeb.2017.329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 321 |
Lingvay I. Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice 2017;23:831-40. [DOI: 10.4158/ep161725.ra] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 322 |
Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin 2017;33:1861-8. [PMID: 28548024 DOI: 10.1080/03007995.2017.1335638] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 323 |
Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes 2017; 8(6): 270-277 [PMID: 28694927 DOI: 10.4239/wjd.v8.i6.270] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 324 |
Owens DR, Monnier L, Barnett AH. Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes Obes Metab 2017;19:1339-52. [PMID: 28432748 DOI: 10.1111/dom.12977] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 325 |
Wilding J, Bailey C, Rigney U, Blak B, Kok M, Emmas C. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes. 2017;11:437-444. [PMID: 28583425 DOI: 10.1016/j.pcd.2017.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 326 |
Cheruvallath ZS, Gwaltney SL, Sabat M, Tang M, Wang H, Jennings A, Hosfield D, Lee B, Wu Y, Halkowycz P, Grimshaw CE. Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators. Bioorganic & Medicinal Chemistry Letters 2017;27:2678-82. [DOI: 10.1016/j.bmcl.2017.04.041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 327 |
Wang Z, Xu D, Huang L, Zhang T, Wang J, Chen Q, Kong L, Zhou X. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes. Diabetes Res Clin Pract 2017;130:77-85. [PMID: 28575729 DOI: 10.1016/j.diabres.2017.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 328 |
Chen X, Wu Z, Chen Y, Wang X, Zhu J, Wang N, Jiang Q, Fu C. Risk score model of type 2 diabetes prediction for rural Chinese adults: the Rural Deqing Cohort Study. J Endocrinol Invest 2017;40:1115-23. [DOI: 10.1007/s40618-017-0680-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 329 |
Goh SY, Hussein Z, Rudijanto A. Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. J Diabetes Investig 2017;8:635-45. [PMID: 28236664 DOI: 10.1111/jdi.12647] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 330 |
Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 2017;77:247-64. [PMID: 28155046 DOI: 10.1007/s40265-017-0694-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 331 |
Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes 2017; 8(4): 154-164 [PMID: 28465792 DOI: 10.4239/wjd.v8.i4.154] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 54] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 332 |
Erickson ML, Little JP, Gay JL, Mccully KK, Jenkins NT. Effects of postmeal exercise on postprandial glucose excursions in people with type 2 diabetes treated with add-on hypoglycemic agents. Diabetes Research and Clinical Practice 2017;126:240-7. [DOI: 10.1016/j.diabres.2017.02.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 333 |
Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, Mauldin PD. Regional, Geographic, and Ethnic Differences in Medication Adherence among Adults with Type 2 Diabetes. Ann Pharmacother 2011;45:169-78. [DOI: 10.1345/aph.1p442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 334 |
Lunghi C, Zongo A, Moisan J, Grégoire JP, Guénette L. Factors associated with antidiabetic medication non-adherence in patients with incident comorbid depression. J Diabetes Complications 2017;31:1200-6. [PMID: 28325698 DOI: 10.1016/j.jdiacomp.2017.02.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 335 |
McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, Glon RM, McCarter JP, Volek JS, Phinney SD. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. JMIR Diabetes 2017;2:e5. [PMID: 30291062 DOI: 10.2196/diabetes.6981] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 336 |
Rehni AK, Liu A, Perez-Pinzon MA, Dave KR. Diabetic aggravation of stroke and animal models. Exp Neurol 2017;292:63-79. [PMID: 28274862 DOI: 10.1016/j.expneurol.2017.03.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 337 |
Meetoo DD, Wong L. To test or not to test? Blood glucose monitoring in type 2 diabetes mellitus. British Journal of Healthcare Management 2017;23:96-101. [DOI: 10.12968/bjhc.2017.23.3.96] [Reference Citation Analysis]
|
| 338 |
Vinayagam R, Xiao J, Xu B. An insight into anti-diabetic properties of dietary phytochemicals. Phytochem Rev 2017;16:535-53. [DOI: 10.1007/s11101-017-9496-2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 339 |
Rathmann W, Strassburger K, Bongaerts B, Bobrov P, Kuss O, Müssig K, Markgraf DF, Szendroedi J, Herder C, Roden M; GDS Group. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes. Diabetes Obes Metab 2017;19:866-73. [PMID: 28127851 DOI: 10.1111/dom.12894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 340 |
McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2017;19:628-34. [PMID: 28026908 DOI: 10.1111/dom.12865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 341 |
Martin CL. Case Study 1. Diabetes Educ 2017;33:6S-13S. [DOI: 10.1177/0145721706298434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 342 |
López-Sepúlveda R, García Lirola MÁ, Espínola García E, Jurado Martínez JM, Martín Sances S, Anaya Ordóñez S, Cabeza Barrera J. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014. Prim Care Diabetes 2017;11:254-64. [PMID: 28126469 DOI: 10.1016/j.pcd.2017.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 343 |
Duke SO. Herbicide and Pharmaceutical Relationships. Weed sci 2010;58:334-9. [DOI: 10.1614/ws-09-102.1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 344 |
Echtay A, Andari E, Atallah P, Moufarrege R, Nemr R. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup. Ethn Dis 2017;27:45-54. [PMID: 28115821 DOI: 10.18865/ed.27.1.45] [Reference Citation Analysis]
|
| 345 |
Bin rsheed A, Chenoweth I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes 2017; 8(1): 28-39 [PMID: 28138362 DOI: 10.4239/wjd.v8.i1.28] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 346 |
Snijder MB, Agyemang C, Peters RJ, Stronks K, Ujcic-Voortman JK, van Valkengoed IG. Case Finding and Medical Treatment of Type 2 Diabetes among Different Ethnic Minority Groups: The HELIUS Study. J Diabetes Res 2017;2017:9896849. [PMID: 28154830 DOI: 10.1155/2017/9896849] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 347 |
Van Olmen J, Kegels G, Korachais C, de Man J, Van Acker K, Kalobu JC, van Pelt M, Ku GM, Hen H, Kanda D, Malombo B, Darras C, Schellevis F. The effect of text message support on diabetes self-management in developing countries - A randomised trial. J Clin Transl Endocrinol 2017;7:33-41. [PMID: 29067248 DOI: 10.1016/j.jcte.2016.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 348 |
Jee Y, Seo M, Yoo B, Hong S, Cho C, Cho Y, Oh J, Shin K. Accuracy of Capillary Blood Glucose Test When Fasting in Diabetes Patients or General Population: Performance Evaluation of G300 Based on ISO 15197:2013 Standards. Korean J Health Promot 2017;17:259. [DOI: 10.15384/kjhp.2017.17.4.259] [Reference Citation Analysis]
|
| 349 |
Rhee SY, Kim HJ, Ko SH, Hur KY, Kim NH, Moon MK, Park SO, Lee BW, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association. Monotherapy in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2017;41:349-56. [PMID: 29086532 DOI: 10.4093/dmj.2017.41.5.349] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 350 |
Baruah MP, Kalra S, Bose S, Deka J. An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort. Indian J Endocrinol Metab 2017;21:443-52. [PMID: 28553603 DOI: 10.4103/ijem.IJEM_548_16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 351 |
Nückel M. Risikofaktoren eines Schlaganfalls. Fachwissen Pflege 2017. [DOI: 10.1007/978-3-662-53625-4_4] [Reference Citation Analysis]
|
| 352 |
Kim KJ, Choi JH, Kim KJ, An JH, Kim HY, Kim SG, Kim NH. Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus. Diabetes Metab J 2017;41:284-95. [PMID: 28868826 DOI: 10.4093/dmj.2017.41.4.284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 353 |
Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association. Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. Diabetes Metab J 2017;41:337-48. [PMID: 29086531 DOI: 10.4093/dmj.2017.41.5.337] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 354 |
Migdal AL, Herzlinger S, Abrahamson MJ. Treating Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-20797-1_44-2] [Reference Citation Analysis]
|
| 355 |
Lee BW, Kim JH, Ko SH, Hur KY, Kim NH, Rhee SY, Kim HJ, Moon MK, Park SO, Choi KM; Committee of Clinical Practice Guideline of Korean Diabetes Association. Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017. Diabetes Metab J 2017;41:367-73. [PMID: 29086534 DOI: 10.4093/dmj.2017.41.5.367] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 356 |
Fairchild PC, Nathan AG, Quinn M, Huang ES, Laiteerapong N. Patients' Future Expectations for Diabetes and Hypertension Treatments: "Through the Diet… I Think This is Going to Go Away.". J Gen Intern Med 2017;32:49-55. [PMID: 27730483 DOI: 10.1007/s11606-016-3871-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 357 |
Migdal AL, Herzlinger S, Abrahamson MJ. Treating Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_44] [Reference Citation Analysis]
|
| 358 |
Fleischmann H, Göke R, Bramlage P. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering. Diabetes Metab Syndr 2017;11 Suppl 1:S91-7. [PMID: 27986406 DOI: 10.1016/j.dsx.2016.12.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 359 |
Makhoul I, Yacoub A, Siegel E. Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study. SAGE Open Med 2016;4:2050312116682257. [PMID: 28348740 DOI: 10.1177/2050312116682257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 360 |
Caballero AE. Long-term studies of treatments for type 2 diabetes. Postgrad Med 2017;129:352-65. [PMID: 27882816 DOI: 10.1080/00325481.2017.1265417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 361 |
. Managing Type 2 Diabetes in the Elderly. Diabetes Educ 2002;28:3-11. [DOI: 10.1177/014572170202800114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 362 |
Koski RR. Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus. Diabetes Educ 2006;32:869-76. [DOI: 10.1177/0145721706294260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 363 |
Yu MK, Kim SH. Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. Clin J Am Soc Nephrol 2016;11:2104-6. [PMID: 27827307 DOI: 10.2215/CJN.10361016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 364 |
Romera I, Ampudia-blasco FJ, Pérez A, Ariño B, Pfarr E, Giljanovic Kis S, Naderali E. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition) 2016;63:519-526. [DOI: 10.1016/j.endoen.2016.11.001] [Reference Citation Analysis]
|
| 365 |
Saulnier PJ, Wheelock KM, Howell S, Weil EJ, Tanamas SK, Knowler WC, Lemley KV, Mauer M, Yee B, Nelson RG, Beisswenger PJ. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. Diabetes 2016;65:3744-53. [PMID: 27609106 DOI: 10.2337/db16-0310] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 366 |
Luizon MR, Eckalbar WL, Wang Y, Jones SL, Smith RP, Laurance M, Lin L, Gallins PJ, Etheridge AS, Wright F, Zhou Y, Molony C, Innocenti F, Yee SW, Giacomini KM, Ahituv N. Genomic Characterization of Metformin Hepatic Response. PLoS Genet 2016;12:e1006449. [PMID: 27902686 DOI: 10.1371/journal.pgen.1006449] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 367 |
Campbell RK. Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother 2007;41:51-60. [DOI: 10.1345/aph.1h459] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 368 |
. New data from the FIELD study: protecting the diabetic eye. Diabetes and Vascular Disease Research 2007;4:S1-7. [DOI: 10.3132/dvdr.2007.069] [Reference Citation Analysis]
|
| 369 |
Hermans MP. Diabetic macro- and microvascular disease in type 2 diabetes. Diabetes and Vascular Disease Research 2007;4:S7-S11. [DOI: 10.3132/dvdr.2007.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 370 |
. The developing role of metformin (Glucophage®) in the treatment of type 2 diabetes. Diabetes and Vascular Disease Research 2006;3:S1-7. [DOI: 10.3132/dvdr.2006.032] [Reference Citation Analysis]
|
| 371 |
Barreto MN, Cesse EÂ, Lima RF, Marinho MG, Specht Yda S, de Carvalho EM, Fontbonne A. Analysis of access to hypertensive and diabetic drugs in the Family Health Strategy, State of Pernambuco, Brazil. Rev Bras Epidemiol 2015;18:413-24. [PMID: 26083512 DOI: 10.1590/1980-5497201500020010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 372 |
Guimarães J. Diabetes-Old Therapies Revisited. EMIJ 2016;3. [DOI: 10.15406/emij.2016.03.00056] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 373 |
Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes 2016;9:347-53. [PMID: 27877058 DOI: 10.2147/DMSO.S121770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 374 |
Einarson TR, Bereza BG, Acs A, Jensen R. Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes. Curr Med Res Opin 2017;33:331-58. [PMID: 27819150 DOI: 10.1080/03007995.2016.1257977] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 375 |
Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function. J Clin Endocrinol Metab 2016;101:4076-84. [PMID: 27533307 DOI: 10.1210/jc.2016-2056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 376 |
Umpierrez GE. When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 2016;22:12-14. [DOI: 10.1016/s1530-891x(20)42964-7] [Reference Citation Analysis]
|
| 377 |
Bode B. When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 2016;22:14-22. [DOI: 10.1016/s1530-891x(20)42965-9] [Reference Citation Analysis]
|
| 378 |
Garber AJ. The History of Insulin Technology: A Brief Review of the Updates in Basal Insulin Therapy Through the Years. Endocrine Practice 2016;22:7-9. [DOI: 10.4158/1934-2403-22.s5.1] [Reference Citation Analysis]
|
| 379 |
Garber AJ. When and how to Use Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 2016;22:9-12. [DOI: 10.1016/s1530-891x(20)42963-5] [Reference Citation Analysis]
|
| 380 |
Zonszein J, Groop PH. Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther 2016;7:621-39. [PMID: 27796904 DOI: 10.1007/s13300-016-0208-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 381 |
Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther 2016;7:825-45. [PMID: 27787778 DOI: 10.1007/s13300-016-0206-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 382 |
Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Postgrad Med 2016;128:731-9. [PMID: 27690710 DOI: 10.1080/00325481.2016.1241663] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 383 |
Kondo T, Goto R, Ono K, Kitano S, Suico MA, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E. Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial. Sci Rep 2016;6:35690. [PMID: 27759092 DOI: 10.1038/srep35690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 384 |
Abdulsalim S, Peringadi Vayalil M, Miraj SS. New fixed dose chemical combinations: the way forward for better diabetes type II management? Expert Opinion on Pharmacotherapy 2016;17:2207-14. [DOI: 10.1080/14656566.2016.1241235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 385 |
Cron L, Allen T, Febbraio MA. The role of gp130 receptor cytokines in the regulation of metabolic homeostasis. J Exp Biol 2016;219:259-65. [PMID: 26792338 DOI: 10.1242/jeb.129213] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 386 |
Pintaudi B, Di Vieste G, Bonomo M. The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes. Int J Endocrinol 2016;2016:9132052. [PMID: 27807448 DOI: 10.1155/2016/9132052] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 387 |
Mata-Cases M, Franch-Nadal J, Real J, Mauricio D. Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. BMJ Open 2016;6:e012463. [PMID: 27707830 DOI: 10.1136/bmjopen-2016-012463] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 388 |
Stiefelhagen P. Vieles spricht für eine initiale Kombinationstherapie. MMW - Fortschritte der Medizin 2016;158:20-20. [DOI: 10.1007/s15006-016-8752-5] [Reference Citation Analysis]
|
| 389 |
Stiefelhagen P. Vieles spricht für eine initiale Kombitherapie bei Typ-2-Diabetes. Info Diabetol 2016;10:47-48. [DOI: 10.1007/s15034-016-0953-6] [Reference Citation Analysis]
|
| 390 |
Jin HY, Park TS, Lee KA, Baek YH. THE INFLUENCE OF TOTAL OR SUB-TOTAL GASTRECTOMY ON GLUCOSE CONTROL IN DIABETIC AND NON-DIABETIC PATIENTS. Acta Endocrinol (Buchar) 2016;12:423-30. [PMID: 31149126 DOI: 10.4183/aeb.2016.423] [Reference Citation Analysis]
|
| 391 |
Meetoo DD, Ochieng B, Wong L, Fatani T. Self-monitoring of blood glucose: Is it justified? Nurse Prescribing 2016;14:S10-S15. [DOI: 10.12968/npre.2016.14.sup10.s10] [Reference Citation Analysis]
|
| 392 |
Fiesselmann A, Wiesner T, Fleischmann H, Bramlage P. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin. Acta Diabetol 2016;53:717-26. [PMID: 27093968 DOI: 10.1007/s00592-016-0862-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 393 |
Ampudia-blasco F, Perelló Camacho E. Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:1013-1025. [DOI: 10.1016/j.med.2016.09.011] [Reference Citation Analysis]
|
| 394 |
Suzuki K, Mitsuma Y, Sato T, Anraku T, Hatta M. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes. J Clin Med Res 2016;8:805-14. [PMID: 27738482 DOI: 10.14740/jocmr2741w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 395 |
Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev 2016;9:CD006992. [PMID: 27640062 DOI: 10.1002/14651858.CD006992.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 396 |
Balkau B, Halimi S, Blickle JF, Vergès B, Avignon A, Attali C, Chartier I, Amelineau E. Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study. Ann Endocrinol (Paris) 2016;77:649-57. [PMID: 27646493 DOI: 10.1016/j.ando.2016.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 397 |
Bain SC, Feher M, Russell-Jones D, Khunti K. Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes Obes Metab 2016;18:1157-66. [PMID: 27491724 DOI: 10.1111/dom.12760] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 398 |
Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin: 在磺脲类药物单用或与二甲双胍联用血糖控制不佳的中国2型糖尿病患者中西格列汀的安全性和有效性评估:一项随机对照研究. Journal of Diabetes 2017;9:667-76. [DOI: 10.1111/1753-0407.12456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 399 |
Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Review of Clinical Pharmacology 2016;9:1453-62. [DOI: 10.1080/17512433.2016.1221758] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 400 |
Pafili K, Maltezos E, Papanas N. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1367-80. [DOI: 10.1080/17425255.2016.1229302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 401 |
Singh KA, Devi R K B, Singh KL. Β-CELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW. jemds 2016;5:5315-5321. [DOI: 10.14260/jemds/2016/1204] [Reference Citation Analysis]
|
| 402 |
Gu J, Meng X, Guo Y, Wang L, Zheng H, Liu Y, Wu B, Wang D. The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Sci Rep 2016;6:32714. [PMID: 27600499 DOI: 10.1038/srep32714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 403 |
Kanzer-lowis G. Early Combination Therapy With a Thiazolidinedione for the Treatment of Type 2 Diabetes. Diabetes Educ 2003;29:954-61. [DOI: 10.1177/014572170302900605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 404 |
Chandalia HB, Thadani PM. Glycemic targets in diabetes. Int J Diabetes Dev Ctries 2016;36:359-369. [DOI: 10.1007/s13410-016-0467-8] [Reference Citation Analysis]
|
| 405 |
Tian J, Lian F, Yu X, Cui Y, Zhao T, Cao Y, Tong X. The Efficacy and Safety of Chinese Herbal Decoction in Type 2 Diabetes: A 5-Year Retrospective Study. Evid Based Complement Alternat Med 2016;2016:5473015. [PMID: 27656237 DOI: 10.1155/2016/5473015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 406 |
Romera I, Ampudia-Blasco FJ, Pérez A, Ariño B, Pfarr E, Giljanovic Kis S, Naderali E. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinol Nutr 2016;63:519-26. [PMID: 27578024 DOI: 10.1016/j.endonu.2016.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 407 |
Levy JC. Review: UKPDS odyssey — 2001. Diabetes & Vascular Disease 2001;1:14-21. [DOI: 10.1177/14746514010010010301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 408 |
Reasner CA, Göke B. Overcoming the barriers to effective glycaemic control for type 2 diabetes. Diabetes & Vascular Disease 2002;2:290-5. [DOI: 10.1177/14746514020020041001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 409 |
Bailey CJ, Day C. Review: Thiazolidinediones today. Diabetes & Vascular Disease 2001;1:7-13. [DOI: 10.1177/14746514010010010201] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 410 |
Emslie-smith A, Dowall J, Morris A. The problem of polypharmacy in type 2 diabetes. Diabetes & Vascular Disease 2003;3:54-6. [DOI: 10.1177/14746514030030010901] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 411 |
Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov. 2016;15:786-804. [PMID: 27516169 DOI: 10.1038/nrd.2016.151] [Cited by in Crossref: 176] [Cited by in F6Publishing: 180] [Article Influence: 25.1] [Reference Citation Analysis]
|
| 412 |
Pan C, Han P, Ji Q, Li C, Lu J, Yang J, Li W, Zeng J, Hsieh A, Chan J. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong: 阿格列汀治疗2型糖尿病患者的疗效和安全性:在中国大陆,台湾,香港进行的一项多中心随机双盲安慰剂对照的3期研究. Journal of Diabetes 2017;9:386-95. [DOI: 10.1111/1753-0407.12425] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 413 |
Cahn A, Cefalu WT. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. Diabetes Care 2016;39 Suppl 2:S137-45. [PMID: 27440826 DOI: 10.2337/dcS15-3007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 414 |
Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab 2016;18:990-8. [PMID: 27282621 DOI: 10.1111/dom.12704] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 415 |
Saunders WB, Nguyen H, Kalsekar I. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study. Diabetes Metab Syndr Obes 2016;9:217-23. [PMID: 27486339 DOI: 10.2147/DMSO.S103972] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 416 |
Kaduskar PU. Biosimilar insulins: An unavoidable option in South-East Asia. Indian J Endocrinol Metab 2016;20:574-5. [PMID: 27366730 DOI: 10.4103/2230-8210.183462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 417 |
Koski RR. Oral Antidiabetic Agents: A Comparative Review. Journal of Pharmacy Practice 2004;17:39-48. [DOI: 10.1177/0897190003261307] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 418 |
Kakara M, Nomura H, Ezaki M, Fukae M, Hirota T, Matsubayashi S, Hirakawa M, Ieiri I. Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. J Diabetes Complications 2016;30:1282-6. [PMID: 27338508 DOI: 10.1016/j.jdiacomp.2016.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 419 |
. Whence and whither the fixed-dose combination? Diabetes and Vascular Disease Research 2005;2:51-3. [DOI: 10.3132/dvdr.2005.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 420 |
Blevins T, Pieber TR, Colón Vega G, Zhang S, Bastyr EJ 3rd, Chang AM; IMAGINE 4 Investigators. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab 2016;18:1072-80. [PMID: 27234693 DOI: 10.1111/dom.12696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 421 |
Özmen Ö, Topsakal S. İNSAN VE HAYVANLARDA DİABETES MELLİTUS. Mehmet Akif Ersoy Üniversitesi Veteriner Fakültesi Dergisi 2016;1:47-47. [DOI: 10.24880/maeuvfd.260791] [Reference Citation Analysis]
|
| 422 |
AlSaggaf W, Asiri M, Ajlan B, Afif AB, Khalil R, Salman AB, Alghamdi A, Bashawieh O, Alamoudi A, Aljahdali A, Aljahdali N, Patwa H, Bakhaidar M, Bahijri SM, Ahmed M, Al-Shali K, Bokhari S, Alhozali A, Borai A, Ajabnoor G, Tuomilehto J. Reported Benefits of Insulin Therapy for Better Glycemic Control in Type 2 Diabetic Patients-Is This Applicable in Saudi Patients? Clin Med Insights Endocrinol Diabetes 2016;9:13-7. [PMID: 27330334 DOI: 10.4137/CMED.S38077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 423 |
Kabade DM, Koppad A, Khatawkar A, Kabade SD, Ahmed A. ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS. jebmh 2016;3:2272-2282. [DOI: 10.18410/jebmh/2016/503] [Reference Citation Analysis]
|
| 424 |
Trastulli S, Desiderio J, Grandone I, Fontana L, Paolini L, Altomare M, D'Angelo P, Palazzi M, Cirocchi R, Leotta S, Fatati G, Parisi A; ESINODOP trial Investigators. Rationale and design of the Early Sleeve gastrectomy In New Onset Diabetic Obese Patients (ESINODOP) trial. Endocrine 2017;55:748-53. [PMID: 27259508 DOI: 10.1007/s12020-016-0996-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 425 |
Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov 2016;15:639-60. [PMID: 27256476 DOI: 10.1038/nrd.2016.75] [Cited by in Crossref: 405] [Cited by in F6Publishing: 416] [Article Influence: 57.9] [Reference Citation Analysis]
|
| 426 |
Schwartz SS, Jellinger PS, Herman ME. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile. Postgraduate Medicine 2016;128:609-19. [DOI: 10.1080/00325481.2016.1191955] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 427 |
Moreno-ulloa A, Moreno-ulloa J. Mortality reduction among persons with type 2 diabetes: (−)-Epicatechin as add-on therapy to metformin? Medical Hypotheses 2016;91:86-9. [DOI: 10.1016/j.mehy.2016.04.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 428 |
Weng W, Liang Y, Kimball ES, Hobbs T, Kong S, Sakurada B, Bouchard J. Longitudinal Changes in Medical Services and Related Costs in a Single Cohort of Patients Newly Diagnosed With Type 2 Diabetes, 2006 to 2012. Clinical Therapeutics 2016;38:1314-26. [DOI: 10.1016/j.clinthera.2016.03.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 429 |
Owen KR. Treating young adults with type 2 diabetes or monogenic diabetes. Best Pract Res Clin Endocrinol Metab 2016;30:455-67. [PMID: 27432078 DOI: 10.1016/j.beem.2016.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 430 |
Chien MN, Chen YL, Hung YJ, Wang SY, Lu WT, Chen CH, Lin CL, Huang TP, Tsai MH, Tseng WK, Wu TJ, Ho C, Lin WY, Chen B, Chuang LM. Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. J Diabetes Investig 2016;7:881-8. [PMID: 27181199 DOI: 10.1111/jdi.12532] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 431 |
Lu J, Ji W, Zhao M, Wang M, Yan W, Chen M, Ren S, Yuan B, Wang B, Chen L. Protamine zinc insulin combined with sodium selenite improves glycometabolism in the diabetic KKAy mice. Sci Rep 2016;6:26563. [PMID: 27212152 DOI: 10.1038/srep26563] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 432 |
Ji L, Pan C, Lu J, Li H, Zhu D, Li Q, Li Q, Peng Y, Tian H, Yao C, Zhao Z, Wang L, Wang B; for the VISION Study Group. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diabetes Obes Metab 2016;18:775-82. [DOI: 10.1111/dom.12667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 433 |
Kassahun A, Gashe F, Mulisa E, Rike WA. Nonadherence and factors affecting adherence of diabetic patients to anti-diabetic medication in Assela General Hospital, Oromia Region, Ethiopia. J Pharm Bioallied Sci 2016;8:124-9. [PMID: 27134464 DOI: 10.4103/0975-7406.171696] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 434 |
Schernthaner-Reiter MH, Schernthaner G. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Rev Endocrinol Metab 2016;11:281-96. [PMID: 30058933 DOI: 10.1586/17446651.2016.1151783] [Reference Citation Analysis]
|
| 435 |
Sarras P M. A Potential gDNA Methylation Epigenetic Mechanism to Explain the Long Term Complications of Type 1 and 2 Diabetes. MOJAP 2016;2. [DOI: 10.15406/mojap.2016.02.00049] [Reference Citation Analysis]
|
| 436 |
Bramlage P, Bluhmki T, Rathmann W, Kaltheuner M, Beyersmann J, Danne T; DIVE study group. Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy. Diabetes Res Clin Pract 2016;116:127-35. [PMID: 27321328 DOI: 10.1016/j.diabres.2016.03.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 437 |
Attimarad M. Multivariate optimization of a capillary zone electrophoresis assay method for simultaneous quantification of metformin and vildagliptin from a formulation. Journal of Liquid Chromatography & Related Technologies 2016;39:401-7. [DOI: 10.1080/10826076.2016.1169426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 438 |
Bonora E, Cigolini M. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutrition, Metabolism and Cardiovascular Diseases 2016;26:273-84. [DOI: 10.1016/j.numecd.2016.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 439 |
Mast MR, Walraven I, Hoekstra T, Jansen AP, van der Heijden AA, Elders PJ, Heine RJ, Dekker JM, Nijpels G, Hugtenburg JG. Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System. Diabet Med 2016;33:794-802. [PMID: 26946450 DOI: 10.1111/dme.13110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 440 |
Hong JY, Park KY, Kim BJ, Hwang WM, Kim DH, Lim DM. Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients. Endocrinol Metab (Seoul) 2016;31:80-5. [PMID: 26676329 DOI: 10.3803/EnM.2016.31.1.80] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 441 |
Lepelley M, Giai J, Yahiaoui N, Chanoine S, Villier C. Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University. J Diabetes Res 2016;2016:3545914. [PMID: 27034959 DOI: 10.1155/2016/3545914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 442 |
Mata-cases M, Mauricio D, Franch-nadal J. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets: 使用基础胰岛素治疗后空腹血糖控制充分但HbA1c未达标的2型糖尿病患者的临床特征. J Diabetes 2017;9:34-44. [DOI: 10.1111/1753-0407.12373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 443 |
Mellor DD, Naumovski N. Effect of cocoa in diabetes: the potential of the pancreas and liver as key target organs, more than an antioxidant effect? Int J Food Sci Technol 2016;51:829-41. [DOI: 10.1111/ijfs.13075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 444 |
Leontovich AA, Intine RV, Sarras MP Jr. Epigenetic Studies Point to DNA Replication/Repair Genes as a Basis for the Heritable Nature of Long Term Complications in Diabetes. J Diabetes Res 2016;2016:2860780. [PMID: 26981540 DOI: 10.1155/2016/2860780] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 445 |
Quek R, Bi X, Henry CJ. Impact of protein-rich meals on glycaemic response of rice. Br J Nutr 2016;115:1194-201. [PMID: 26856623 DOI: 10.1017/S0007114515005498] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 446 |
Lankisch MR, Del Prato S, Dain M, Mullins P, Owens DR. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. Primary Care Diabetes 2016;10:51-9. [DOI: 10.1016/j.pcd.2015.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 447 |
Lin J, Zhou S, Wei W, Pan C, Lingohr-smith M, Levin P. Does Clinical Inertia Vary By Personalized A1C Goal? A Study of Predictors And Prevalence of Clinical Inertia In A U.S. Managed-Care Setting. Endocrine Practice 2016;22:151-61. [DOI: 10.4158/ep15868.or] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 448 |
Kumar S, Pathak AK, Saikia D, Kumar A. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. J Clin Diagn Res 2015;9:FC07-10. [PMID: 26816909 DOI: 10.7860/JCDR/2015/17027.6888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 449 |
Durán-garcia S, Lee J, Yki-järvinen H, Rosenstock J, Hehnke U, Thiemann S, Patel S, Woerle H. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. Diabet Med 2016;33:926-33. [DOI: 10.1111/dme.13041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 450 |
Mcardle MA, Kennedy EB, Roche HM. Linking Inflammation, Obesity, and Diabetes. Metabolic Syndrome 2016. [DOI: 10.1007/978-3-319-11251-0_29] [Reference Citation Analysis]
|
| 451 |
Depaula AL, Depaula CCL, Ugale S. Ileal Interposition with Sleeve Gastrectomy for the Treatment of Type 2 Diabetes. Metabolic Syndrome and Diabetes 2016. [DOI: 10.1007/978-1-4939-3220-7_15] [Reference Citation Analysis]
|
| 452 |
Migdal AL, Abrahamson MJ. Treating Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2016. [DOI: 10.1007/978-3-319-20797-1_44-1] [Reference Citation Analysis]
|
| 453 |
de Vries McClintock HF, Morales KH, Small DS, Bogner HR. Patterns of Adherence to Oral Hypoglycemic Agents and Glucose Control among Primary Care Patients with Type 2 Diabetes. Behav Med 2016;42:63-71. [PMID: 24673362 DOI: 10.1080/08964289.2014.904767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 454 |
Ligthart S, van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, van Hoek M, Sijbrands EJ, Franco OH, Dehghan A. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 2016;4:44-51. [PMID: 26575606 DOI: 10.1016/S2213-8587(15)00362-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 125] [Article Influence: 21.9] [Reference Citation Analysis]
|
| 455 |
Tsapas A, Karagiannis T, Bekiari E. Premixed insulin regimens for type 2 diabetes. Endocrine 2016;51:387-9. [PMID: 26649859 DOI: 10.1007/s12020-015-0821-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 456 |
Zeitler P, Chou HS, Copeland KC, Geffner M. Clinical trials in youth-onset type 2 diabetes: needs, barriers, and options. Curr Diab Rep 2015;15:28. [PMID: 25777998 DOI: 10.1007/s11892-015-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 457 |
Zeitler P, Hirst K, Copeland KC, El Ghormli L, Levitt Katz L, Levitsky LL, Linder B, McGuigan P, White NH, Wilfley D; TODAY Study Group. HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes. Diabetes Care 2015;38:2285-92. [PMID: 26537182 DOI: 10.2337/dc15-0848] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 458 |
Retnakaran R. Novel Strategies for Inducing Glycemic Remission during the Honeymoon Phase of Type 2 Diabetes. Canadian Journal of Diabetes 2015;39:S142-7. [DOI: 10.1016/j.jcjd.2015.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 459 |
Rapoport M, Harel N, Shasha Y, Barkan R, Kitaee E, Buchs A, Izhakian S, Aviel-gadot E. Achievement of partial combined control of major diabetes targets in primary care correlates with development of chronic complications in T2DM patients—A real life data. Primary Care Diabetes 2015;9:412-7. [DOI: 10.1016/j.pcd.2015.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 460 |
Akahori H. Clinical evaluation of thrice-daily lispro 50/50 versus twice-daily aspart 70/30 on blood glucose fluctuation and postprandial hyperglycemia in patients with type 2 diabetes mellitus. Diabetol Int 2015;6:275-283. [DOI: 10.1007/s13340-014-0196-5] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 461 |
Torre C, Guerreiro J, de Oliveira Martins S, Raposo JF, Martins AP, Leufkens H. Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. Primary Care Diabetes 2015;9:482-9. [DOI: 10.1016/j.pcd.2015.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 462 |
Kim YA, Yoo WS, Hong ES, Ku EJ, Park KS, Lim S, Cho YM, Park KS, Jang HC, Choi SH. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. Diabetes Metab J 2015;39:489-97. [PMID: 26616595 DOI: 10.4093/dmj.2015.39.6.489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 463 |
Kim HJ, Jin BY, Oh MJ, Shin KH, Choi SH, Kim DH. The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiol Behav 2016;154:184-90. [PMID: 26631545 DOI: 10.1016/j.physbeh.2015.11.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 464 |
Wang L, Wu C, Shen L, Liu H, Chen Y, Liu F, Wang Y, Yang J. Evaluation of drug–drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males. Xenobiotica 2015;46:703-8. [DOI: 10.3109/00498254.2015.1113576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 465 |
Kim SS, Kim IJ, Kim YK, Yoon KH, Son HY, Park SW, Sung YA, Baek HS. Insulin Initiation in Insulin-Naïve Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study. Diabetes Metab J 2015;39:481-8. [PMID: 26616594 DOI: 10.4093/dmj.2015.39.6.481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 466 |
Cătoi AF, Pârvu A, Mureşan A, Busetto L. Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery. Obes Facts 2015;8:350-63. [PMID: 26584027 DOI: 10.1159/000441259] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 467 |
Mittermayer F, Caveney E, De Oliveira C, Gourgiotis L, Puri M, Tai LJ, Turner JR. Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. Curr Diabetes Rev 2015;11:17-31. [PMID: 25537454 DOI: 10.2174/1573399810666141224121927] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 468 |
Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A, Abe N, Arai K, Fujiya H, Fukumoto Y, Dake F, Iizumi T, Ito M, Iwasaki K, Kanamori A, Kato S, Kato M, Kawara A, Kimura K, Chikamori K, Iemitsu K, Kou S, Kudo M, Kurihara Y, Lee G, Tsuruoka A, Manda N, Matoba K, Hayashi H, Minami M, Kuribayashi N, Miyazawa K, Chiba Y, Osonoi T, Nakamura S, Sasaki H, Komori K, Oishi M, Okada A, Okuguchi F, Yanagisawa M, Sugimoto H, Sugiyama H, Takai M, Takaki M, Takamura H, Takeda H, Takeda H, Tanaka K, Miwa T, Tomonaga O, Taguchi M, Yamazaki K, Wada T, Yagi N, Yamaoka K, Yuhara A; Japan Diabetes Clinical Data Management Study Group (JDDM). Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). J Diabetes Investig 2016;7:386-95. [PMID: 27330726 DOI: 10.1111/jdi.12430] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 469 |
Kaku K, Eid MA. Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan. J Diabetes Investig 2015;6:610-9. [PMID: 26543532 DOI: 10.1111/jdi.12348] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 470 |
Firth CL, Sazie E, Hedberg K, Drach L, Maher J. Female Inmates with Diabetes: Results from Changes in a Prison Food Environment. Women's Health Issues 2015;25:732-8. [DOI: 10.1016/j.whi.2015.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 471 |
Pittas AG, Westcott GP, Balk EM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3:886-94. [PMID: 26341170 DOI: 10.1016/S2213-8587(15)00280-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 472 |
Pak J, Kwon Y, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. Impact of gastrointestinal bypass on nonmorbidly obese type 2 diabetes mellitus patients after gastrectomy. Surgery for Obesity and Related Diseases 2015;11:1266-72. [DOI: 10.1016/j.soard.2014.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 473 |
Kim M, Kim H, Han J, Ji E, Kim A. Physicochemical Analysis and Quality Characteristics of Jerusalem Artichoke and Mook Prepared with Jerusalem Artichoke Powder. Korean J Food and Nutr 2015;28:635-642. [DOI: 10.9799/ksfan.2015.28.4.635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 474 |
Lee KP. Psycholosocial factors associated with psychological insulin resistance in primary care patients in Hong Kong. J Clin Transl Endocrinol 2015;2:157-62. [PMID: 29159120 DOI: 10.1016/j.jcte.2015.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 475 |
Mogre V, Apala P, Nsoh JA, Wanaba P. Adiposity, hypertension and weight management behaviours in Ghanaian type 2 diabetes mellitus patients aged 20-70 years. Diabetes Metab Syndr 2016;10:S79-85. [PMID: 26522828 DOI: 10.1016/j.dsx.2015.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 476 |
de Bruin TW, Reele S, Hamer-maansson JE, Parikh S, Tang W. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clinical Pharmacology in Drug Development 2016;5:118-30. [DOI: 10.1002/cpdd.220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 477 |
Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 2015;1353:113-37. [PMID: 26448515 DOI: 10.1111/nyas.12939] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 478 |
Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. Arch Pharm Res 2016;39:259-70. [DOI: 10.1007/s12272-015-0621-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 479 |
Danne T, Bluhmki T, Seufert J, Kaltheuner M, Rathmann W, Beyersmann J, Bramlage P; DIVE study group. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord 2015;15:54. [PMID: 26446863 DOI: 10.1186/s12902-015-0051-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 480 |
Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine 2015;127:808-17. [DOI: 10.1080/00325481.2015.1085293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 481 |
Engelbrechtsen L, Andersson E, Roepstorff S, Hansen T, Vestergaard H. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. Pharmacogenetics and Genomics 2015;25:475-84. [DOI: 10.1097/fpc.0000000000000160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 482 |
Davidson JA. Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. Postgraduate Medicine 2015;127:827-41. [DOI: 10.1080/00325481.2015.1096743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 483 |
Derosa G, D’angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. Pharmacological Research 2015;100:127-34. [DOI: 10.1016/j.phrs.2015.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 484 |
Soong YY, Lim J, Sun L, Henry CJ. Effect of co-ingestion of amino acids with rice on glycaemic and insulinaemic response. Br J Nutr 2015;114:1845-51. [PMID: 26420496 DOI: 10.1017/S0007114515003645] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 485 |
Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol 2015;14:129. [PMID: 26415691 DOI: 10.1186/s12933-015-0294-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 486 |
Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 487 |
Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA; NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015;17:1056-64. [PMID: 26179619 DOI: 10.1111/dom.12539] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 488 |
Wu W, Li Y, Chen X, Lin D, Xiang S, Shen F, Gu X. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Med Sci Monit 2015;21:2678-84. [PMID: 26350766 DOI: 10.12659/MSM.894026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 489 |
Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). Diabetes Obes Metab 2015;17:1133-41. [PMID: 26085028 DOI: 10.1111/dom.12528] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 490 |
Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. Diabetes Care 2015;38:1742-9. [PMID: 26153271 DOI: 10.2337/dc14-2830] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 491 |
Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence 2015;9:1225-31. [PMID: 26346988 DOI: 10.2147/PPA.S87935] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 492 |
Hanefeld M. Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab 2014;40:391-9. [PMID: 25451189 DOI: 10.1016/j.diabet.2014.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 493 |
Moghissi ES. Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination. J Am Osteopath Assoc 2014;114:S22-9. [PMID: 24769505 DOI: 10.7556/jaoa.2014.086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 494 |
Macha S, Brand T, Meinicke T, Link J, Broedl UC. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Clinical Therapeutics 2015;37:1789-96. [DOI: 10.1016/j.clinthera.2015.06.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 495 |
Irace C, Tripolino C, Carallo C, Scavelli FB, Valle ED, Cortese C, Gnasso A. Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes: . Journal of Investigative Medicine 2015;63:802-5. [DOI: 10.1097/jim.0000000000000210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 496 |
Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle H, Broedl UC. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 2015;37:1773-1788.e1. [DOI: 10.1016/j.clinthera.2015.05.511] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 497 |
Mohamed AI, Mohamed FA, Ahmed S, Mohamed YAS. An efficient hydrophilic interaction liquid chromatographic method for the simultaneous determination of metformin and pioglitazone using high-purity silica column. Journal of Chromatography B 2015;997:16-22. [DOI: 10.1016/j.jchromb.2015.05.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 498 |
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019. [PMID: 27189025 DOI: 10.1038/nrdp.2015.19] [Cited by in Crossref: 865] [Cited by in F6Publishing: 881] [Article Influence: 108.1] [Reference Citation Analysis]
|
| 499 |
Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, Sihabout A, Salamucha I, Coleman CI. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. Diabet Med 2015;32:1530-40. [PMID: 26104021 DOI: 10.1111/dme.12837] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 500 |
Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 2015;17:1033-41. [PMID: 26094974 DOI: 10.1111/dom.12507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 501 |
Ioacara S, Guja C, Reghina A, Martin S, Sirbu A, Fica S. Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine. J Diabetes Res 2015;2015:962346. [PMID: 26176017 DOI: 10.1155/2015/962346] [Reference Citation Analysis]
|
| 502 |
Merker L, Häring HU, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND MET investigators. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med 2015;32:1555-67. [PMID: 26031566 DOI: 10.1111/dme.12814] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 503 |
Sarras MP Jr, Leontovich AA, Intine RV. Use of zebrafish as a model to investigate the role of epigenetics in propagating the secondary complications observed in diabetes mellitus. Comp Biochem Physiol C Toxicol Pharmacol 2015;178:3-7. [PMID: 26165618 DOI: 10.1016/j.cbpc.2015.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 504 |
Pi-sunyer FX. The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight. Postgraduate Medicine 2015;120:5-17. [DOI: 10.3810/pgm.2008.07.1785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 505 |
Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial. J Diabetes 2016;8:405-13. [PMID: 25952532 DOI: 10.1111/1753-0407.12312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 506 |
Inzucchi SE, Tunceli K, Qiu Y, Rajpathak S, Brodovicz KG, Engel SS, Mavros P, Radican L, Brudi P, Li Z, Fan CP, Hanna B, Tang J, Blonde L. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Diabetes Obes Metab 2015;17:956-64. [PMID: 25962401 DOI: 10.1111/dom.12489] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 507 |
de Vries McClintock HF, Wiebe DJ, OʼDonnell AJ, Morales KH, Small DS, Bogner HR. Neighborhood social environment and patterns of adherence to oral hypoglycemic agents among patients with type 2 diabetes mellitus. Fam Community Health 2015;38:169-79. [PMID: 25739064 DOI: 10.1097/FCH.0000000000000069] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 508 |
Johnston CA, Moreno JP, Foreyt JP. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Curr Atheroscler Rep 2014;16:457. [PMID: 25288176 DOI: 10.1007/s11883-014-0457-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 509 |
Bernecker K, Job V. Beliefs About Willpower Are Related to Therapy Adherence and Psychological Adjustment in Patients With Type 2 Diabetes. Basic and Applied Social Psychology 2015;37:188-95. [DOI: 10.1080/01973533.2015.1049348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 510 |
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288-2296. [PMID: 26063450 DOI: 10.1093/eurheartj/ehv239] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 22.9] [Reference Citation Analysis]
|
| 511 |
Hermanns N, Kulzer B, Kohlmann T, Jacob S, Landgraf W, Theobald K, Haak T. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial. Health Qual Life Outcomes 2015;13:77. [PMID: 26055391 DOI: 10.1186/s12955-015-0279-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 512 |
Sorkin DH, Billimek J, August KJ, Ngo-Metzger Q, Kaplan SH, Reikes AR, Greenfield S. Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes. Fam Pract 2015;32:317-22. [PMID: 25846216 DOI: 10.1093/fampra/cmv014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 513 |
Liao HY, Sun MF, Lin JG, Chang SL, Lee YC. Electroacupuncture plus metformin lowers glucose levels and facilitates insulin sensitivity by activating MAPK in steroid-induced insulin-resistant rats. Acupunct Med 2015;33:388-94. [PMID: 26025384 DOI: 10.1136/acupmed-2014-010724] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 514 |
Mamza J, Mehta R, Donnelly R, Idris I. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study. Diabetes Ther 2015;6:213-26. [PMID: 26014844 DOI: 10.1007/s13300-015-0110-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 515 |
Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-24. [PMID: 24831734 DOI: 10.1007/s40265-014-0225-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 516 |
Lin X, Choi D, Hong J. Insulin particles as building blocks for controlled insulin release multilayer nano-films. Mater Sci Eng C Mater Biol Appl 2015;54:239-44. [PMID: 26046287 DOI: 10.1016/j.msec.2015.05.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 517 |
Choi HY, Kim YH, Kim MJ, Lee SH, Bang K, Han S, Lim HS, Bae KS. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D 2014;14:165-76. [PMID: 24962635 DOI: 10.1007/s40268-014-0054-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 518 |
Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2015;17:699-702. [DOI: 10.1111/dom.12469] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 519 |
Riyaz M. IMPORTANCE OF THYROID FUNCTION TEST IN DIABETES. jebmh 2015;2:2822-2828. [DOI: 10.18410/jebmh/2015/412] [Reference Citation Analysis]
|
| 520 |
Schwartz S, Herman M. Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. Postgrad Med 2015;127:480-93. [PMID: 25913393 DOI: 10.1080/00325481.2015.1043182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 521 |
Kleinberger JW, Pollin TI. Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci 2015;1346:45-56. [PMID: 25907167 DOI: 10.1111/nyas.12757] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 522 |
Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle HJ, Broedl UC. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:665-74. [PMID: 25772548 DOI: 10.1111/dom.12464] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 523 |
Bhosle DS, Bhagat AH, Patil AD, Bobde JA, Bhagat AA. Effects of a fixed-dose combination of sitagliptin and metformin versus respective monotherapies in newly diagnosed type 2 diabetic subjects. Int J Diabetes Dev Ctries 2017;37:16-20. [DOI: 10.1007/s13410-015-0370-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 524 |
Treviño S, Sánchez-Lara E, Sarmiento-Ortega VE, Sánchez-Lombardo I, Flores-Hernández JÁ, Pérez-Benítez A, Brambila-Colombres E, González-Vergara E. Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model. J Inorg Biochem 2015;147:85-92. [PMID: 25920353 DOI: 10.1016/j.jinorgbio.2015.04.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 525 |
Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One 2015;10:e0121915. [PMID: 25849542 DOI: 10.1371/journal.pone.0121915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 526 |
Kim JH, Ahn JH, Kim SK, Lee DH, Kim HS, Shon HS, Jeon HJ, Kim TH, Cho YW, Kim JT, Han SM, Chung CH, Ryu OH, Lee JM, Lee SH, Kwon MJ, Kim TK, Namgoong IS, Kim ES, Jung IK, Moon SD, Han JH, Kim CH, Cho EH, Kim KY, Park HB, Lee KS, Lee SW, Lee SC, Kang CM, Jeon BS, Song MS, Yun SB, Chung HK, Seong JH, Jeong JY, Cha BY. Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. J Diabetes Investig 2015;6:219-26. [PMID: 25802730 DOI: 10.1111/jdi.12261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 527 |
Ekström N, Svensson AM, Miftaraj M, Andersson Sundell K, Cederholm J, Zethelius B, Eliasson B, Gudbjörnsdottir S. Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). BMJ Open Diabetes Res Care 2015;3:e000059. [PMID: 25815205 DOI: 10.1136/bmjdrc-2014-000059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 528 |
Mccoy EK, Wright BM. A Review of Insulin Pen Devices. Postgraduate Medicine 2015;122:81-8. [DOI: 10.3810/pgm.2010.05.2145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 529 |
Jellinger PS. Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 2015;123:53-65. [DOI: 10.3810/pgm.2011.01.2245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 530 |
Jia Y, Lao Y, Leung SW. Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis. BMJ Open 2015;5:e006139. [PMID: 25762228 DOI: 10.1136/bmjopen-2014-006139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 531 |
Abdul-ghani M, Defronzo RA, Eldor R. Combination therapy in type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch46] [Reference Citation Analysis]
|
| 532 |
Lebovitz HE, Melander A. Sulfonylureas and meglitinides: insights into physiology and translational clinical utility. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 533 |
Zhou M, Li Z, Min R, Dong Y, Sun Q, Li Y. Log (TG)/HDL-C ratio as a predictor of decreased islet beta cell function in patients with type 2 diabetes: 6-year cohort study. J Diabetes 2015;7:689-98. [PMID: 25327383 DOI: 10.1111/1753-0407.12229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 534 |
Pérez-maraver M, Romero Meliá G, Caballero Corchuelo J. Eficacia y seguridad de una estrategia basal plus en pacientes con diabetes mellitus tipo 2 en la práctica clínica especializada. El estudio Basal Plus en España. Avances en Diabetología 2015;31:64-71. [DOI: 10.1016/j.avdiab.2015.01.001] [Reference Citation Analysis]
|
| 535 |
Truong V, Helmy R, Ren S, Schenk D, Waterhouse D. Application of HPLC mixed-mode chromatography in determining radiochemical purity of [(14) C] labeled metformin hydrochloride. J Labelled Comp Radiopharm 2015;58:177-9. [PMID: 25720824 DOI: 10.1002/jlcr.3264] [Reference Citation Analysis]
|
| 536 |
White JR. Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus: A Review of the Evidence. Ann Pharmacother 2015;49:582-98. [DOI: 10.1177/1060028015573564] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 537 |
Neumiller JJ. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. Clin Diabetes 2014;32:170-7. [PMID: 25646943 DOI: 10.2337/diaclin.32.4.170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 538 |
Wang MC, Guo XH, Zhang Y, Zhang YL, Zhang HH, Zhang YC. Laparoscopic Roux-en-Y Gastric Bypass versus Sleeve Gastrectomy for Obese Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. The American Surgeon 2015;81:166-71. [DOI: 10.1177/000313481508100229] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 539 |
Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:223-42. [PMID: 24407560 DOI: 10.1007/s40265-013-0169-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 540 |
Stein CM, Kramer CK, Zinman B, Choi H, Opsteen C, Retnakaran R. Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes. Diabet Med 2015;32:645-52. [PMID: 25495067 DOI: 10.1111/dme.12671] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 541 |
Gavin JR 3rd, Jones MR, Ford DM, Truitt KE. Safety and efficacy of colesevelam HCl in the treatment of elderly patients. Drugs Aging 2014;31:461-70. [PMID: 24777691 DOI: 10.1007/s40266-014-0174-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 542 |
Karakaya M, Kürekçi M, Eskiyurt B, Sert Y, Çırak Ç. Experimental and computational study on molecular structure and vibrational analysis of an antihyperglycemic biomolecule: Gliclazide. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2015;135:137-46. [DOI: 10.1016/j.saa.2014.06.152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 543 |
Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X, Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z, Lin S, Zeng L, Yan J, Ji L, Weng J. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med 2015;277:137-50. [PMID: 25039675 DOI: 10.1111/joim.12293] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 544 |
Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia 2015;58:50-8. [PMID: 25205223 DOI: 10.1007/s00125-014-3372-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 545 |
Mcardle MA, Kennedy EB, Roche HM. Linking Inflammation, Obesity and Diabetes. Metabolic Syndrome 2015. [DOI: 10.1007/978-3-319-12125-3_29-1] [Reference Citation Analysis]
|
| 546 |
Singh AK. Science of premix insulin: where have we reached? Expert Rev Endocrinol Metab 2015;10:65-74. [PMID: 30289040 DOI: 10.1586/17446651.2015.961914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 547 |
Kabadi UM, Kabadi MU, Weber S, Bubolz A, Finnerty E. Progressive <I>β</i> Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy? JDM 2015;05:21-27. [DOI: 10.4236/jdm.2015.51003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 548 |
Rhee KJ, Lee CG, Kim SW, Gim DH, Kim HC, Jung BD. Extract of Ginkgo Biloba Ameliorates Streptozotocin-Induced Type 1 Diabetes Mellitus and High-Fat Diet-Induced Type 2 Diabetes Mellitus in Mice. Int J Med Sci 2015;12:987-94. [PMID: 26664261 DOI: 10.7150/ijms.13339] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 549 |
Weems P, Cooper M. Pancreas transplantation in type II diabetes mellitus. World J Transplant 2014; 4(4): 216-221 [PMID: 25540731 DOI: 10.5500/wjt.v4.i4.216] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 550 |
Takasu T, Hayashizaki Y, Tahara A, Kurosaki E, Takakura S. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. Clin Exp Pharmacol Physiol 2015;42:87-93. [DOI: 10.1111/1440-1681.12317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 551 |
Patel N, Stone MA, McDonough C, Davies MJ, Khunti K, Eborall H. Concerns and perceptions about necessity in relation to insulin therapy in an ethnically diverse UK population with Type 2 diabetes: a qualitative study focusing mainly on people of South Asian origin. Diabet Med 2015;32:635-44. [PMID: 25439281 DOI: 10.1111/dme.12648] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 552 |
Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab 2015;17:179-87. [PMID: 25406730 DOI: 10.1111/dom.12414] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 553 |
Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 2014;57:2475-84. [PMID: 25208756 DOI: 10.1007/s00125-014-3360-3] [Cited by in Crossref: 90] [Cited by in F6Publishing: 98] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 554 |
Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. Diabetes Care 2014;37:3188-95. [PMID: 25231895 DOI: 10.2337/dc14-0874] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 555 |
Blonde L, San Juan ZT, Bolton P. Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice 2014;20:1322-32. [DOI: 10.4158/ep14259.ra] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 556 |
Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-8. [PMID: 25249651 DOI: 10.2337/dc14-0893] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 557 |
Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis‐d'agostino D, Bailes Z, Thiemann S, Patel S, Woerle H, von Eynatten M. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial. Diabetes Obes Metab 2015;17:136-44. [DOI: 10.1111/dom.12399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 558 |
Pound LD, Kievit P, Grove KL. The nonhuman primate as a model for type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2014;21:89-94. [PMID: 24569549 DOI: 10.1097/MED.0000000000000043] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 559 |
Plosker GL. Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes. Drugs 2014;74:2191-209. [DOI: 10.1007/s40265-014-0324-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 560 |
Hsieh CJ, Shen FC. The durability of sitagliptin in elderly patients with type 2 diabetes. Clin Interv Aging. 2014;9:1905-1911. [PMID: 25422588 DOI: 10.2147/cia.s72396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 561 |
Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15:851-863. [PMID: 24646052 DOI: 10.1517/14656566.2014.898750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 562 |
Pérez A, Mediavilla J, Miñambres I, González-segura D. Glycemic control in patients with type 2 diabetes mellitus in Spain. Revista Clínica Española (English Edition) 2014;214:429-36. [DOI: 10.1016/j.rceng.2014.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 563 |
Kamuhabwa AR, Charles E. Predictors of poor glycemic control in type 2 diabetic patients attending public hospitals in Dar es Salaam. Drug Healthc Patient Saf 2014;6:155-65. [PMID: 25368533 DOI: 10.2147/DHPS.S68786] [Cited by in Crossref: 51] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 564 |
Meah F, Juneja R. Insulin tactics in type 2 diabetes. Med Clin North Am 2015;99:157-86. [PMID: 25456649 DOI: 10.1016/j.mcna.2014.08.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 565 |
Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015;99:87-106. [PMID: 25456645 DOI: 10.1016/j.mcna.2014.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 566 |
Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15:2565-2585. [PMID: 25316597 DOI: 10.1517/14656566.2014.968551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 567 |
Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabet Med 2014;31:1293-300. [DOI: 10.1111/dme.12561] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 568 |
Broichhagen J, Schönberger M, Cork SC, Frank JA, Marchetti P, Bugliani M, Shapiro AM, Trapp S, Rutter GA, Hodson DJ, Trauner D. Optical control of insulin release using a photoswitchable sulfonylurea. Nat Commun 2014;5:5116. [PMID: 25311795 DOI: 10.1038/ncomms6116] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 569 |
Stoneman A, Atkinson D, Davey M, Marley JV. Quality improvement in practice: improving diabetes care and patient outcomes in Aboriginal Community Controlled Health Services. BMC Health Serv Res 2014;14:481. [PMID: 25288282 DOI: 10.1186/1472-6963-14-481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 570 |
Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. Diabetes Res Clin Pract 2015;107:104-12. [PMID: 25458330 DOI: 10.1016/j.diabres.2014.09.047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 571 |
Simon AC, Bolli GB, Dain MP, Wang E, Holleman F. Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI. Nutr Metab Cardiovasc Dis 2014;24:1354-9. [PMID: 25261909 DOI: 10.1016/j.numecd.2014.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 572 |
Modi H, Cornu M, Thorens B. Glutamine stimulates biosynthesis and secretion of insulin-like growth factor 2 (IGF2), an autocrine regulator of beta cell mass and function. J Biol Chem 2014;289:31972-82. [PMID: 25271169 DOI: 10.1074/jbc.M114.587733] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 573 |
Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation. 2014;129:2305-2312. [PMID: 24891623 DOI: 10.1161/circulationaha.113.006985] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 574 |
Lin SD, Tsai ST, Tu ST, Su CC, Chen JF, Lu CH, Wang CH, Yu NC, Hsu SR, Hsieh MC. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes. Prim Care Diabetes 2015;9:135-41. [PMID: 25266893 DOI: 10.1016/j.pcd.2014.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 575 |
Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obes Metab 2014;16:1239-46. [DOI: 10.1111/dom.12377] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 576 |
Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, Rossi da Silva ME. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study. Diabetol Metab Syndr 2014;6:103. [PMID: 25285158 DOI: 10.1186/1758-5996-6-103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 577 |
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig. 2015;6:182-191. [PMID: 25802726 DOI: 10.1111/jdi.12282] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 578 |
Kamenov Z. Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data. Diabetes Ther 2014;5:483-98. [PMID: 25245616 DOI: 10.1007/s13300-014-0083-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 579 |
Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials. Clin Ther 2014;36:1595-605. [PMID: 25236917 DOI: 10.1016/j.clinthera.2014.07.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 580 |
Chen TY, Hsieh CJ. Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus. Postgrad Med 2014;126:205-15. [PMID: 24918804 DOI: 10.3810/pgm.2014.05.2768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 581 |
Banerji MA, Baron MA, Gao L, Blonde L. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. Postgrad Med 2014;126:111-25. [PMID: 24918797 DOI: 10.3810/pgm.2014.05.2761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 582 |
Green JB. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. Postgrad Med 2014;126:190-204. [PMID: 24918803 DOI: 10.3810/pgm.2014.05.2767] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 583 |
Zhang X, Brooks B, Molyneaux L, Landy E, Banatwalla R, Wu T, Wong J, Su B, Yue DK. Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity. Int J Endocrinol 2014;2014:354040. [PMID: 25180036 DOI: 10.1155/2014/354040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 584 |
Yin J, Deng H, Qin S, Tang W, Zeng L, Zhou B. Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 2014;105:e10-5. [DOI: 10.1016/j.diabres.2014.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 585 |
Dhliwayo N, Sarras MP Jr, Luczkowski E, Mason SM, Intine RV. Parp inhibition prevents ten-eleven translocase enzyme activation and hyperglycemia-induced DNA demethylation. Diabetes 2014;63:3069-76. [PMID: 24722243 DOI: 10.2337/db13-1916] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 586 |
Zhao G, Dharmadhikari G, Maedler K, Meyer-Hermann M. Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. PLoS Comput Biol 2014;10:e1003798. [PMID: 25167060 DOI: 10.1371/journal.pcbi.1003798] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 587 |
Sunaert P, Willems S, Feyen L, Bastiaens H, De Maeseneer J, Jenkins L, Nobels F, Samyn E, Vandekerckhove M, Wens J. Engaging GPs in insulin therapy initiation: a qualitative study evaluating a support program in the Belgian context. BMC Fam Pract. 2014;15:144. [PMID: 25145469 DOI: 10.1186/1471-2296-15-144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 588 |
Daniele G, Abdul-Ghani M, DeFronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 2014;15:2003-18. [PMID: 25139488 DOI: 10.1517/14656566.2014.944160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 589 |
Thanabalasingham G, Owen KR. Type 2 diabetes in the young: why we should worry. Pract Diab 2014;31:225-7. [DOI: 10.1002/pdi.1873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 590 |
Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P, Mpoulimari I, Kokkali C, Dimoulou G, Rodopolou P, Stefanidis I, Kent DM, Hadjigeorgiou GM. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther 2014;36:1443-53.e9. [PMID: 25109773 DOI: 10.1016/j.clinthera.2014.06.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 591 |
Afshar M, Memarian R, Mohammadi E. The Effect of Group Discussion on the Quality of Life and HbA1c Levels of Adolescents With Diabetes. Iran Red Crescent Med J 2014;16:e21110. [PMID: 25389494 DOI: 10.5812/ircmj.21110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 592 |
Geier AS, Wellmann I, Wellmann J, Kajüter H, Heidinger O, Hempel G, Hense HW. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2014;106:73-80. [PMID: 25139631 DOI: 10.1016/j.diabres.2014.07.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 593 |
Yang W, Xing X, Lv X, Li Y, Ma J, Yuan G, Sun F, Wang W, Woloschak M, Lukashevich V, Kozlovski P, Kothny W; all investigators. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus 中国2型糖尿病患者使用磺脲类药物联合维格列汀可改善血糖控制且无低血糖及体重增加: Vildagliptin add-on to SU in China. Journal of Diabetes 2015;7:174-81. [DOI: 10.1111/1753-0407.12169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 594 |
Liu SC, Chien KL, Wang CH, Chen WC, Leung CH. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract 2013;19:980-8. [PMID: 23807528 DOI: 10.4158/EP13148.OR] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 595 |
Pérez A, Mediavilla JJ, Miñambres I, González-Segura D. Glycemic control in patients with type 2 diabetes mellitus in Spain. Rev Clin Esp (Barc) 2014;214:429-36. [PMID: 25016415 DOI: 10.1016/j.rce.2014.05.028] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 596 |
Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D'Agostino D, Woerle HJ. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med 2014;31:1505-14. [PMID: 24824197 DOI: 10.1111/dme.12495] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 597 |
Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc 2014;7:267-82. [PMID: 25061317 DOI: 10.2147/JMDH.S64084] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 598 |
Agarwal S, Singh B, Wadhwa R. Insulin glargine as add-on therapy to oral hypoglycaemic agents to achieve target fasting plasma glucose levels in type 2 diabetes patients in an Indian setup. Indian Journal of Medical Specialities 2014;5:89-92. [DOI: 10.7713/ijms.2014.0002] [Reference Citation Analysis]
|
| 599 |
Bhattacharyya A, Shetty R, Rajkumar C, Bantwal G. Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A1 chieve study. Indian J Endocrinol Metab 2014;18:480-5. [PMID: 25143902 DOI: 10.4103/2230-8210.137490] [Reference Citation Analysis]
|
| 600 |
Cardoso V. Regimes terapêuticos e controlo glicémico nos diabéticos tipo 2 de uma unidade de saúde familiar. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2014;9:129-135. [DOI: 10.1016/j.rpedm.2014.08.001] [Reference Citation Analysis]
|
| 601 |
Joshi SR, Ramachandran A, Chadha M, Chatterjee S, Rathod R, Kalra S. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 2014;15:1611-20. [DOI: 10.1517/14656566.2014.932771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 602 |
Li WX, Gou JF, Tian JH, Yan X, Yang L. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Curr Ther Res Clin Exp 2010;71:211-38. [PMID: 24688145 DOI: 10.1016/j.curtheres.2010.08.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 603 |
Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig 2014;5:134-41. [PMID: 24843750 DOI: 10.1111/jdi.12206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 604 |
Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 2014;7:129-36. [PMID: 24971031 DOI: 10.2147/PGPM.S50288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 605 |
Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications 2014;28:831-5. [PMID: 25104238 DOI: 10.1016/j.jdiacomp.2014.06.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 606 |
Camara S, Bouenizabila E, Hermans MP, Ahn SA, Rousseau MF. Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. Diabetes Metab Syndr 2014;8:145-51. [PMID: 25220917 DOI: 10.1016/j.dsx.2014.04.037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 607 |
Blonde L, Baron MA, Zhou R, Banerji MA. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors. Postgrad Med 2014;126:172-89. [PMID: 24918802 DOI: 10.3810/pgm.2014.05.2766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 608 |
Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014;3:212262. [PMID: 24991224 DOI: 10.7573/dic.212262] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 609 |
de Vries McClintock HF, Morales KH, Small DS, Bogner HR. A brief adherence intervention that improved glycemic control: mediation by patterns of adherence. J Behav Med 2015;38:39-47. [PMID: 24913600 DOI: 10.1007/s10865-014-9576-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 610 |
Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-8. [PMID: 24827939 DOI: 10.1111/dom.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 611 |
Hajjaji I, Shah S, Li Y, Prusty V, Benabbas Y, Home PD. Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve study. Diabetes Ther 2014;5:113-26. [PMID: 24477669 DOI: 10.1007/s13300-014-0052-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 612 |
Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9. [PMID: 24722494 DOI: 10.2337/dc13-2105] [Cited by in Crossref: 265] [Cited by in F6Publishing: 282] [Article Influence: 29.4] [Reference Citation Analysis]
|
| 613 |
Gaál Z, Papp Z, Bakó B. Evaluation of the DIABOBHU Observational Study. Orvosi Hetilap 2014;155:903-910. [DOI: 10.1556/oh.2014.29927] [Reference Citation Analysis]
|
| 614 |
Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, Yu DM. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr 2014;6:69. [PMID: 24917890 DOI: 10.1186/1758-5996-6-69] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 615 |
Rozenberg K, Smirin P, Sampson SR, Rosenzweig T. Insulin-sensitizing and insulin-mimetic activities of Sarcopoterium spinosum extract. J Ethnopharmacol 2014;155:362-72. [PMID: 24882728 DOI: 10.1016/j.jep.2014.05.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 616 |
Samad MB, Kabir AU, D'Costa NM, Akhter F, Ahmed A, Jahan MR, Hannan JM. Ethanolic Extract of Butea monosperma Leaves Elevate Blood Insulin Level in Type 2 Diabetic Rats, Stimulate Insulin Secretion in Isolated Rat Islets, and Enhance Hepatic Glycogen Formation. Evid Based Complement Alternat Med 2014;2014:356290. [PMID: 24860609 DOI: 10.1155/2014/356290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 617 |
Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M, Honda T, Kume S, Matsumoto K. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Eur J Pharmacol 2014;737:194-201. [PMID: 24858371 DOI: 10.1016/j.ejphar.2014.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 618 |
Takahara M, Shiraiwa T, Ohtoshi K, Kaneto H, Katakami N, Matsuoka TA, Shimomura I. Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy. J Diabetes Investig 2012;3:510-6. [PMID: 24843616 DOI: 10.1111/j.2040-1124.2012.00223.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 619 |
Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Takahara S, Nagashima K, Hosokawa M, Seino Y, Inagaki N. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig 2011;2:297-303. [PMID: 24843502 DOI: 10.1111/j.2040-1124.2010.00096.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 620 |
Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Takahara S, Seino Y, Inagaki N. Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load. J Diabetes Investig 2011;2:429-34. [PMID: 24843526 DOI: 10.1111/j.2040-1124.2011.00126.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 621 |
Mamza J, Mehta R, Idris I. Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study. BMJ Open Diabetes Res Care 2014;2:e000021. [PMID: 25452865 DOI: 10.1136/bmjdrc-2014-000021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 622 |
Chacra AR. Evolving Metformin Treatment Strategies in Type-2 Diabetes: From Immediate-Release Metformin Monotherapy to Extended-Release Combination Therapy. American Journal of Therapeutics 2014;21:198-210. [DOI: 10.1097/mjt.0b013e318235f1bb] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 623 |
Rees TM, Curtis BH, Gaskins KA, Sierra-johnson J, Jiang HH, Liu R, Holcombe JH. Efficacy and Safety of Insulin Lispro in Obese Patients with Type 2 Diabetes: A Retrospective Meta-Analysis of 7 Randomized Controlled Trials. Endocrine Practice 2014;20:389-98. [DOI: 10.4158/ep13301.or] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 624 |
Nauck MA, Haastert B, Trautner C, Müller UA, Nauck MA, Heinemann L; Clinical Trials Study Group of the German Association for the Study of Diabetes (Deutsche Diabetes-Gesellschaft). A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. Diabetologia 2014;57:868-77. [PMID: 24445534 DOI: 10.1007/s00125-014-3168-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 625 |
. Retracted : Executive dysfunction in elderly diabetic patients. Geriatrics & Gerontology International 2015;15:1106-1106. [DOI: 10.1111/ggi.12288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 626 |
Pouwer F, Nefs G, Nouwen A. Adverse effects of depression on glycemic control and health outcomes in people with diabetes: a review. Endocrinol Metab Clin North Am 2013;42:529-44. [PMID: 24011885 DOI: 10.1016/j.ecl.2013.05.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 627 |
Sicras-mainar A, Navarro-artieda R, Ibáñez-nolla J. Clinical and economic characteristics associated with type 2 diabetes. Revista Clínica Española (English Edition) 2014;214:121-30. [DOI: 10.1016/j.rceng.2014.01.001] [Reference Citation Analysis]
|
| 628 |
Wang M, Liu Y, Li X. Type-2 diabetes management using Analytic Hierarchy Process and Analytic Network Process. Proceedings of the 11th IEEE International Conference on Networking, Sensing and Control 2014. [DOI: 10.1109/icnsc.2014.6819703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 629 |
Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, Chung CH, Park JH, Jang HC, Choi DS. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig 2014;5:701-8. [PMID: 25422771 DOI: 10.1111/jdi.12201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 630 |
Kakorin SV, Averkova IA, Mkrtumyan AM. Hypoglycemic therapy in patients with type 2 diabetes and chronic heart failure. CardioSomatics 2014;5:33-40. [DOI: 10.26442/cs45071] [Reference Citation Analysis]
|
| 631 |
Muñoz Torres M. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research. Endocrinología y Nutrición (English Edition) 2014;61:153-159. [DOI: 10.1016/j.endoen.2014.02.010] [Reference Citation Analysis]
|
| 632 |
Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 2014;31:345-61. [PMID: 24535625 DOI: 10.1007/s12325-014-0102-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 633 |
Witting V, Bergis D, Sadet D, Badenhoop K. Thyroid disease in insulin-treated patients with type 2 diabetes: a retrospective study. Thyroid Res 2014;7:2. [PMID: 24580798 DOI: 10.1186/1756-6614-7-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 634 |
Muñoz Torres M. Degludec, una nueva insulina basal de acción ultra-lenta para el tratamiento de la diabetes tipo 1 y 2: avances en investigación clínica. Endocrinología y Nutrición 2014;61:153-159. [DOI: 10.1016/j.endonu.2013.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 635 |
DeVries JH, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM. A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. Eur Endocrinol 2014;10:23-30. [PMID: 29872460 DOI: 10.17925/EE.2014.10.01.23] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 636 |
Geho WB, Rosenberg LN, Schwartz SL, Lau JR, Gana TJ. A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 2014;8:551-9. [PMID: 24876619 DOI: 10.1177/1932296814524871] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 637 |
Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group. Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31). J Diabetes Investig 2014;5:539-47. [PMID: 25411622 DOI: 10.1111/jdi.12194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 638 |
Moghissi E, Ismail-Beigi F, Devine RC. Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr Pract. 2013;19:526-535. [PMID: 23425655 DOI: 10.4158/ep13005.ra] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 639 |
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes Metab 2014;16:761-5. [PMID: 24447683 DOI: 10.1111/dom.12264] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 640 |
Gauthier B, Singh SR, Virani A, Staples H, Colbourne A. Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes. Can Pharm J (Ott) 2014;147:45-54. [PMID: 24494015 DOI: 10.1177/1715163513506547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 641 |
Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014;174:251-8. [PMID: 24322595 DOI: 10.1001/jamainternmed.2013.12956] [Cited by in Crossref: 310] [Cited by in F6Publishing: 324] [Article Influence: 34.4] [Reference Citation Analysis]
|
| 642 |
Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, Avorn J, Polinski JM. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med 2014;29:320-7. [PMID: 24101534 DOI: 10.1007/s11606-013-2643-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 643 |
Garg SK, Aurand LA, Rimler MS, Dailey GE. Diabetes Duration and the Efficacy and Safety of Insulin Glargine Versus Comparator Treatment in Patients with Type 2 Diabetes Mellitus. Endocrine Practice 2014;20:120-8. [DOI: 10.4158/ep13075.or] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 644 |
Erejuwa OO. Effect of honey in diabetes mellitus: matters arising. J Diabetes Metab Disord 2014;13:23. [PMID: 24476150 DOI: 10.1186/2251-6581-13-23] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 645 |
Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP. Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. Pharmacoepidemiol Drug Saf 2014;23:268-77. [PMID: 24892175 DOI: 10.1002/pds.3559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 646 |
Tahrani AA, Piya MK, Barnett AH. Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 2014;3:671-90. [DOI: 10.1586/17446651.3.6.671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 647 |
Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Review of Endocrinology & Metabolism 2014;4:119-29. [DOI: 10.1586/17446651.4.2.119] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 648 |
Forst T, Pfützner A. Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 2014;8:21-35. [DOI: 10.1586/eem.12.69] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 649 |
Moses RG. Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin. Expert Rev Endocrinol Metab 2010;5:331-42. [PMID: 30861688 DOI: 10.1586/eem.10.17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 650 |
Masini M, Anello M, Bugliani M, Marselli L, Filipponi F, Boggi U, Purrello F, Occhipinti M, Martino L, Marchetti P, De Tata V. Prevention by metformin of alterations induced by chronic exposure to high glucose in human islet beta cells is associated with preserved ATP/ADP ratio. Diabetes Res Clin Pract 2014;104:163-70. [PMID: 24462282 DOI: 10.1016/j.diabres.2013.12.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 651 |
Höer A, Dathe K, Haustein R. Umsatzveränderungen in einzelnen Indikationsgruppen. Arzneimittel-Atlas 2014 2014. [DOI: 10.1007/978-3-662-43447-5_3] [Reference Citation Analysis]
|
| 652 |
Ntaganda JM. Hopf Bifurcation of a Two Delay Mathematical Model of Glucose and Insulin during Physical Activity. OJAppS 2014;04:43-55. [DOI: 10.4236/ojapps.2014.42006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 653 |
Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol 2014;2:30-7. [PMID: 24622667 DOI: 10.1016/S2213-8587(13)70090-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 654 |
Santos MJ, Monteiro M, Pereira P, Freitas M, Marques O. Padrão terapêutico numa população de diabéticos tipo 2: relação com o tempo de doença e nível de cuidados de saúde. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2014;9:15-20. [DOI: 10.1016/j.rpedm.2014.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 655 |
Goodarzi M. Type 2 Diabetes. Reference Module in Biomedical Sciences 2014. [DOI: 10.1016/b978-0-12-801238-3.00011-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 656 |
Chan W, Ngai WWM, Tong PC. Treatment Satisfaction with Insulin Glargine in Insulin-Naïve Type 2 Diabetes Patients—A Hong Kong Based Registry. JDM 2014;04:232-241. [DOI: 10.4236/jdm.2014.43033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 657 |
Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457-466. [PMID: 24320621 DOI: 10.1111/dom.12244] [Cited by in Crossref: 174] [Cited by in F6Publishing: 187] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 658 |
Bebakar WM, Lim-Abrahan MA, Jain AB, Seah D, Soewondo P. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study. Diabetes Res Clin Pract 2013;100 Suppl 1:S17-23. [PMID: 23647713 DOI: 10.1016/S0168-8227(13)70005-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 659 |
Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study. Diabetes Res Clin Pract 2013;100 Suppl 1:S3-9. [PMID: 23647715 DOI: 10.1016/S0168-8227(13)70003-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 660 |
Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J. Clinical and economic characteristics associated with type 2 diabetes. Rev Clin Esp (Barc) 2014;214:121-30. [PMID: 24359793 DOI: 10.1016/j.rce.2013.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 661 |
van Dieren S, Kengne AP, Chalmers J, Beulens JWJ, Davis TME, Fulcher G, Heller SR, Patel A, Colagiuri S, Hamet P, Mancia G, Marre M, Neal B, Williams B, Peelen LM, van der Schouw YT, Woodward M, Zoungas S. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. Diabetes Obes Metab 2014;16:426-32. [DOI: 10.1111/dom.12238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 662 |
Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab 2014;16:443-50. [DOI: 10.1111/dom.12234] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 663 |
Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with good glycemic control among patients with type 2 diabetes mellitus. J Diabetes Investig 2014;5:563-9. [PMID: 25411625 DOI: 10.1111/jdi.12175] [Cited by in Crossref: 44] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 664 |
Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013;67:307-16. [PMID: 23638466 DOI: 10.1111/ijcp.12119] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 665 |
Groves EM, Yu K, Wong ND, Malik S. Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus. Curr Treat Options Cardio Med 2013;15:706-721. [DOI: 10.1007/s11936-013-0273-2] [Reference Citation Analysis]
|
| 666 |
Sims EK, Hatanaka M, Morris DL, Tersey SA, Kono T, Chaudry ZZ, Day KH, Moss DR, Stull ND, Mirmira RG, Evans-Molina C. Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains. Am J Physiol Endocrinol Metab 2013;305:E1495-511. [PMID: 24169046 DOI: 10.1152/ajpendo.00366.2013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 667 |
Bando Y, Ishikura K, Kanehara H, Aoki K, Hisada A, Toya D, Tanaka N. Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes. Diabetol Int 2013;4:251-256. [DOI: 10.1007/s13340-013-0124-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 668 |
Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig 2014;5:581-7. [PMID: 25411627 DOI: 10.1111/jdi.12183] [Cited by in Crossref: 74] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 669 |
Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21. [PMID: 24186878 DOI: 10.2337/dc13-0663] [Cited by in Crossref: 151] [Cited by in F6Publishing: 163] [Article Influence: 15.1] [Reference Citation Analysis]
|
| 670 |
El-Naggar N, Almansari A, Khudada K, Salman S, Mariswamy N, Abdelfattah W, Hashim F. The A1 chieve study - an observational non-interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup analysis of the Gulf population. Int J Clin Pract 2013;67:128-38. [PMID: 23305475 DOI: 10.1111/ijcp.12078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 671 |
Lane WS, Weinrib SL, Rappaport JM, Hale CB, Farmer LK, Lane RS. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Endocr Pract 2013;19:196-201. [PMID: 23186973 DOI: 10.4158/EP12226.OR] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 672 |
Khunti K, Cos X, Rutten G. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes. Prim Care Diabetes 2014;8:119-25. [PMID: 24207030 DOI: 10.1016/j.pcd.2013.09.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 673 |
Gu H, Xia X, Chen Z, Liang H, Yan J, Xu F, Weng J. Insulin therapy improves islet functions by restoring pancreatic vasculature in high-fat diet-fed streptozotocin-diabetic rats (胰岛素治疗通过恢复胰腺血管提高高脂饮食联合链脲佐菌素诱导的糖尿病大鼠的胰岛功能): Insulin therapy and pancreatic vasculature. Journal of Diabetes 2014;6:228-36. [DOI: 10.1111/1753-0407.12095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 674 |
Davidson JA. The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 2013;19:1050-61. [DOI: 10.4158/ep12303.ra] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 675 |
Nefs G, Pop VJ, Denollet J, Pouwer F. The longitudinal association between depressive symptoms and initiation of insulin therapy in people with type 2 diabetes in primary care. PLoS One 2013;8:e78865. [PMID: 24223860 DOI: 10.1371/journal.pone.0078865] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 676 |
Cuddihy RM, Borgman SK. Considerations for Diabetes: Treatment With Insulin Pen Devices. American Journal of Therapeutics 2013;20:694-702. [DOI: 10.1097/mjt.0b013e318217a5e3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 677 |
Sicras Mainar A, Roldán Suárez C, Font Ramos B, Navarro Artieda R, Ibáñez Nolla J. Consecuencias clínicas y económicas de la combinación de metformina con inhibidores de la dipeptidilpeptidasa en pacientes con diabetes tipo 2. Revista Clínica Española 2013;213:377-84. [DOI: 10.1016/j.rce.2013.06.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 678 |
Hermans MP, Elisaf M, Michel G, Muls E, Nobels F, Vandenberghe H, Brotons C; OPTIMISE International Steering Committee. Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care 2013;36:3388-95. [PMID: 23846810 DOI: 10.2337/dc12-1853] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 679 |
Genuth SM. How does pioglitazone prevent progression of impaired glucose tolerance to diabetes? Diabetes 2013;62:3663-5. [PMID: 24158994 DOI: 10.2337/db13-1175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 680 |
Sicras Mainar A, Roldán Suárez C, Font Ramos B, Navarro Artieda R, Ibáñez Nolla J. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. Revista Clínica Española (English Edition) 2013;213:377-84. [DOI: 10.1016/j.rceng.2013.07.006] [Reference Citation Analysis]
|
| 681 |
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-7. [PMID: 23877982 DOI: 10.2337/dc13-0331] [Cited by in Crossref: 431] [Cited by in F6Publishing: 441] [Article Influence: 43.1] [Reference Citation Analysis]
|
| 682 |
Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z. The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A₁chieve observational study. Diabetes Res Clin Pract 2013;101:326-32. [PMID: 24119590 DOI: 10.1016/j.diabres.2013.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 683 |
Zilov A, El Naggar N, Shah S, Shen C, Haddad J. Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A₁chieve observational study. Diabetes Res Clin Pract 2013;101:317-25. [PMID: 24119589 DOI: 10.1016/j.diabres.2013.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 684 |
Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract 2013;67:1283-93. [PMID: 24118640 DOI: 10.1111/ijcp.12308] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 685 |
Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 2013;67:1283-1293. [PMID: 24118640 DOI: 10.1111/j.1463-1326.2012.01590.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 686 |
Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale J. Pharmacothérapie du diabète de type 2. Canadian Journal of Diabetes 2013;37:S428-S436. [DOI: 10.1016/j.jcjd.2013.07.006] [Reference Citation Analysis]
|
| 687 |
Wang J, Huang C, Hung Y, Kwok C, Sun J, Pei D, Yang C, Chen C, Lin C, Sheu WH. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Research and Clinical Practice 2013;102:16-24. [DOI: 10.1016/j.diabres.2013.08.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 688 |
Beisswenger PJ, Howell SK, Russell GB, Miller ME, Rich SS, Mauer M. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013;36:3234-9. [PMID: 23780945 DOI: 10.2337/dc12-2689] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 689 |
Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, Balena R. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) 2013;21:238-47. [PMID: 23404788 DOI: 10.1002/oby.20042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 690 |
Visram H. Patient barriers to insulin use in multi-ethnic populations. Can J Diabetes 2013;37:202-4. [PMID: 24070844 DOI: 10.1016/j.jcjd.2013.02.054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 691 |
Malek M, Aghili R, Emami Z, Khamseh ME. Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol 2013;2013:636927. [PMID: 24224094 DOI: 10.1155/2013/636927] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 692 |
Beisswenger PJ, Howell SK, Russell G, Miller ME, Rich SS, Mauer M. Detection of diabetic nephropathy from advanced glycation endproducts (AGEs) differs in plasma and urine, and is dependent on the method of preparation. Amino Acids 2014;46:311-9. [DOI: 10.1007/s00726-013-1533-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 693 |
Oh E, Yoo TK, Park EC. Diabetic retinopathy risk prediction for fundus examination using sparse learning: a cross-sectional study. BMC Med Inform Decis Mak 2013;13:106. [PMID: 24033926 DOI: 10.1186/1472-6947-13-106] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 694 |
Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol 2013;12:129. [PMID: 24007456 DOI: 10.1186/1475-2840-12-129] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 695 |
Chung HS, Suh S, Kim MY, Kim SK, Kim HK, Lee JI, Hur KY, Kim JH, Min YK, Lee MS. Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin. J Diabetes Investig. 2014;5:51-59. [PMID: 24843737 DOI: 10.1111/jdi.12127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 696 |
Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, De Feo P, Reboldi G, Rivellese AA, Trovati M, Zavaroni I; MIND.IT Study Group. Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial. Diabetes Care 2013;36:2566-72. [PMID: 23863908 DOI: 10.2337/dc12-1781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 697 |
Engel SS, Seck TL, Golm GT, Meehan AG, Kaufman KD, Goldstein BJ. Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin. Endocrine Practice 2013;19:751-7. [DOI: 10.4158/ep12436.or] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 698 |
Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med 2013;126:S21-7. [PMID: 23953076 DOI: 10.1016/j.amjmed.2013.06.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 699 |
Gao W, Dong J, Liu J, Li Y, Liu F, Yang L, Zhou X, Liao L. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Obes Metab 2014;16:179-85. [DOI: 10.1111/dom.12193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 700 |
Ortiz MI. Synergistic interaction between metformin and sulfonylureas on diclofenac-induced antinociception measured using the formalin test in rats. Pain Res Manag 2013;18:253-8. [PMID: 23985578 DOI: 10.1155/2013/579183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 701 |
Grunberger G. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin. Postgrad Med 2013;125:79-90. [PMID: 23748509 DOI: 10.3810/pgm.2013.05.2663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 702 |
Attia AK, Ibrahim MM, El-Ries MA. Thermal analysis of some antidiabetic pharmaceutical compounds. Adv Pharm Bull 2013;3:419-24. [PMID: 24312870 DOI: 10.5681/apb.2013.067] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
|
| 703 |
Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;16:215-22. [DOI: 10.1111/dom.12182] [Cited by in Crossref: 77] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 704 |
Ji LN, Pan CY, Lu JM, Li H, Li Q, Li QF, Peng YD, Tian HM, Yao C, Zhao ZG, Zhang RY, Wang XL, Wang L; VISION Study Group. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc Diabetol 2013;12:118. [PMID: 23958390 DOI: 10.1186/1475-2840-12-118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 705 |
Mudaliar S. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes. Int J Clin Pract 2013;67:876-87. [DOI: 10.1111/ijcp.12154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 706 |
Pashkova EI. The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide. Probl Endokrinol (Mosk) 2013;59:50-55. [DOI: 10.14341/probl201359450-55] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 707 |
Corathers SD, Peavie S, Salehi M. Complications of diabetes therapy. Endocrinol Metab Clin North Am. 2013;42:947-970. [PMID: 24286957 DOI: 10.1016/j.ecl.2013.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 708 |
Taylor R. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med 2013;30:267-75. [PMID: 23075228 DOI: 10.1111/dme.12039] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 709 |
Owens DR. Stepwise intensification of insulin therapy in type 2 diabetes management--exploring the concept of the basal-plus approach in clinical practice. Diabet Med 2013;30:276-88. [PMID: 22998363 DOI: 10.1111/dme.12019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 710 |
DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36 Suppl 2:S127-38. [PMID: 23882037 DOI: 10.2337/dcS13-2011] [Cited by in Crossref: 180] [Cited by in F6Publishing: 191] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 711 |
Neutel JM, Zhao C, Karyekar CS. Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. Diabetes Ther 2013;4:269-83. [PMID: 23881432 DOI: 10.1007/s13300-013-0028-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 712 |
Guo X, Liu X, Wang M, Wei F, Zhang Y, Zhang Y. The effects of bariatric procedures versus medical therapy for obese patients with type 2 diabetes: meta-analysis of randomized controlled trials. Biomed Res Int. 2013;2013:410609. [PMID: 23971035 DOI: 10.1155/2013/410609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 713 |
Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33-42. [PMID: 23328275 DOI: 10.1016/j.clinthera.2012.12.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 714 |
Maria Rotella C, Pala L, Mannucci E. Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab 2013;11:137-44. [PMID: 24348585 DOI: 10.5812/ijem.7551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 715 |
Vyas VK, Bhatt HG, Patel PK, Jalu J, Chintha C, Gupta N, Ghate M. CoMFA and CoMSIA studies on C -aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents. SAR and QSAR in Environmental Research 2013;24:519-51. [DOI: 10.1080/1062936x.2012.751553] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 716 |
Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 2013;56:1503-11. [PMID: 23604551 DOI: 10.1007/s00125-013-2905-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 717 |
Chilton R. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. Expert Rev Endocrinol Metab 2013;8:345-9. [PMID: 30736150 DOI: 10.1586/17446651.2013.811849] [Reference Citation Analysis]
|
| 718 |
Bloomgarden ZT, Blonde L, Garber AJ, Wysham CH. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. Endocr Pract 2012;18 Suppl 3:6-26; quiz 27-8. [PMID: 23315305 DOI: 10.4158/EP12300.RA] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 719 |
Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab 2014;16:193-205. [PMID: 23668598 DOI: 10.1111/dom.12129] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 720 |
Bagnasco A, Di Giacomo P, Da Rin Della Mora R, Catania G, Turci C, Rocco G, Sasso L. Factors influencing self-management in patients with type 2 diabetes: a quantitative systematic review protocol. J Adv Nurs. 2014;70:187-200. [PMID: 23763567 DOI: 10.1111/jan.12178] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 721 |
Randeree H, Liebl A, Hajjaji I, Khamseh M, Zajdenverg L, Chen JW, Haddad J. Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis. Diabetes Ther 2013;4:153-66. [PMID: 23757032 DOI: 10.1007/s13300-013-0026-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 722 |
Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo-Controlled Trial. Pharmacotherapy 2013;33:817-26. [DOI: 10.1002/phar.1301] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 723 |
Marathe CS, Rayner CK, Jones KL, Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 2013;44:75-86. [PMID: 23523778 DOI: 10.1016/j.peptides.2013.01.014] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 724 |
Foster PD, Mamdani MM, Juurlink DN, Shah BR, Paterson JM, Gomes T. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. Diabet Med 2013;30:1209-13. [PMID: 23586333 DOI: 10.1111/dme.12214] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 725 |
Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246-255. [PMID: 23707905 DOI: 10.1016/j.ejphar.2013.05.014] [Cited by in Crossref: 202] [Cited by in F6Publishing: 214] [Article Influence: 20.2] [Reference Citation Analysis]
|
| 726 |
Guedes EP, Hohl A, de Melo TG, Lauand F. Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr. 2013;5:25. [PMID: 23697612 DOI: 10.1186/1758-5996-5-25] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 727 |
Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. J Pharmacol Pharmacother 2013;4:27-32. [PMID: 23662021 DOI: 10.4103/0976-500X.107656] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 728 |
Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study. Diabetes Res Clin Pract 2013;100 Suppl 1:S54-9. [PMID: 23647720 DOI: 10.1016/S0168-8227(13)70011-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 729 |
Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). Journal of Diabetes and its Complications 2013;27:280-6. [DOI: 10.1016/j.jdiacomp.2012.12.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 730 |
Jung JA, Kim JR, Kim SR, Kim TE, Lee SY, Ko JW, Huh W. Pharmacokinetics of a fixed-dose combination of mitiglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study. Clin Drug Investig 2012;32:799-804. [PMID: 23100167 DOI: 10.1007/s40261-012-0012-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 731 |
Al-Nozha O, Habib F, Mojaddidi M, El-Bab MF. Body weight reduction and metformin: Roles in polycystic ovary syndrome. Pathophysiology 2013;20:131-7. [PMID: 23608322 DOI: 10.1016/j.pathophys.2013.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 732 |
Consoli A, Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab 2013;15:967-77. [DOI: 10.1111/dom.12101] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 733 |
. Rationale for and Strategies to Achieve Glycemic Control. In: Leahy J, Cefalu W, editors. Insulin Therapy. CRC Press; 2002. pp. 1-11. [DOI: 10.1201/b14038-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 734 |
Spanou M, Tziomalos K. Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus. World J Diabetes 2013; 4(2): 14-18 [PMID: 23593531 DOI: 10.4239/wjd.v4.i2.14] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 735 |
Viollet B, Foretz M. Revisiting the mechanisms of metformin action in the liver. Ann Endocrinol (Paris) 2013;74:123-9. [PMID: 23582849 DOI: 10.1016/j.ando.2013.03.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 736 |
Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 2013;12:62. [PMID: 23574917 DOI: 10.1186/1475-2840-12-62] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 737 |
Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312. [PMID: 23170914 DOI: 10.2165/11209910-000000000-00000] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 738 |
Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors. Ann Pharmacother 2013;47:490-505. [DOI: 10.1345/aph.1r444] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 739 |
Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale J. Pharmacologic Management of Type 2 Diabetes. Canadian Journal of Diabetes 2013;37:S61-8. [DOI: 10.1016/j.jcjd.2013.01.021] [Cited by in Crossref: 89] [Cited by in F6Publishing: 99] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 740 |
Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care 2013;36:1047-55. [PMID: 23520370 DOI: 10.2337/dc12-1805] [Cited by in Crossref: 234] [Cited by in F6Publishing: 234] [Article Influence: 23.4] [Reference Citation Analysis]
|
| 741 |
Derosa G, Cicero AFG, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'angelo A, Fogari E, Maffioli P. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy. Diabet Med 2013;30:846-54. [DOI: 10.1111/dme.12158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 742 |
Gallwitz B, Rosenstock J, Emser A, von Eynatten M, Woerle H. Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA 1c < 7% with no hypoglycaemia and no weight gain over 2 years. Int J Clin Pract 2013;67:317-21. [DOI: 10.1111/ijcp.12101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 743 |
Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-259. [PMID: 23487174 DOI: 10.1124/jpet.113.203364] [Cited by in Crossref: 131] [Cited by in F6Publishing: 143] [Article Influence: 13.1] [Reference Citation Analysis]
|
| 744 |
Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. Drugs 2013;73:327-39. [DOI: 10.1007/s40265-013-0023-5] [Cited by in Crossref: 132] [Cited by in F6Publishing: 143] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 745 |
Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology 2008;48:696-707. [DOI: 10.1177/0091270008316884] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 746 |
Hussey EK, Clark RV, Amin DM, Kipnes MS, O'connor-semmes RL, O'driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJR. Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology 2010;50:623-35. [DOI: 10.1177/0091270009351879] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 747 |
O'Neal DN, Adhya S, Jenkins A, Ward G, Welsh JB, Voskanyan G. Feasibility of adjacent insulin infusion and continuous glucose monitoring via the Medtronic Combo-Set. J Diabetes Sci Technol 2013;7:381-8. [PMID: 23566996 DOI: 10.1177/193229681300700214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 748 |
Griffin S. Insulin treatment of type 2 diabetes: considerations when converting from human insulin to insulin analogs. Ann Med 2013;45:129-40. [PMID: 22758403 DOI: 10.3109/07853890.2012.679959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 749 |
Chatterjee K, Ali KM, De D, Bera TK, Jana K, Maiti S, Ghosh A, Ghosh D. Hyperglycemia-induced alteration in reproductive profile and its amelioration by the polyherbal formulation MTEC (modified) in streptozotocin-induced diabetic albino rats. Biomarkers and Genomic Medicine 2013;5:54-66. [DOI: 10.1016/j.gmbhs.2013.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 750 |
Fonseca V, Staels B, Morgan JD, Shentu Y, Golm GT, Johnson-levonas AO, Kaufman KD, Goldstein BJ, Steinberg H. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and its Complications 2013;27:177-83. [DOI: 10.1016/j.jdiacomp.2012.09.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 751 |
Farmer AJ, Lasserson DS, Perera R, Glasziou PP, Holman R. Different insulin regimens for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2013. [DOI: |
